CN110446783A - The duplication of cyclic DNA or amplification method - Google Patents
The duplication of cyclic DNA or amplification method Download PDFInfo
- Publication number
- CN110446783A CN110446783A CN201880018564.4A CN201880018564A CN110446783A CN 110446783 A CN110446783 A CN 110446783A CN 201880018564 A CN201880018564 A CN 201880018564A CN 110446783 A CN110446783 A CN 110446783A
- Authority
- CN
- China
- Prior art keywords
- sequence
- dna
- oric
- enzyme
- cyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004122 cyclic group Chemical group 0.000 title claims abstract description 301
- 238000000034 method Methods 0.000 title claims abstract description 222
- 230000003321 amplification Effects 0.000 title abstract description 49
- 238000003199 nucleic acid amplification method Methods 0.000 title abstract description 49
- 108020004414 DNA Proteins 0.000 claims abstract description 612
- 102000004190 Enzymes Human genes 0.000 claims abstract description 285
- 108090000790 Enzymes Proteins 0.000 claims abstract description 285
- 238000006243 chemical reaction Methods 0.000 claims abstract description 215
- 102000053602 DNA Human genes 0.000 claims abstract description 104
- 238000000926 separation method Methods 0.000 claims abstract description 66
- 230000010076 replication Effects 0.000 claims abstract description 38
- 230000000977 initiatory effect Effects 0.000 claims abstract description 31
- 238000006555 catalytic reaction Methods 0.000 claims abstract description 29
- 210000000349 chromosome Anatomy 0.000 claims abstract description 20
- 239000012634 fragment Substances 0.000 claims abstract description 17
- 210000004671 cell-free system Anatomy 0.000 claims abstract description 13
- 230000008569 process Effects 0.000 claims description 119
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 150000007523 nucleic acids Chemical class 0.000 claims description 34
- 238000006276 transfer reaction Methods 0.000 claims description 27
- 239000000872 buffer Substances 0.000 claims description 26
- 239000011541 reaction mixture Substances 0.000 claims description 25
- 102000008579 Transposases Human genes 0.000 claims description 24
- 108010020764 Transposases Proteins 0.000 claims description 24
- 230000000295 complement effect Effects 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 230000003362 replicative effect Effects 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 3
- 239000006227 byproduct Substances 0.000 abstract description 16
- 229940088598 enzyme Drugs 0.000 description 255
- 239000000243 solution Substances 0.000 description 126
- 241000588724 Escherichia coli Species 0.000 description 99
- 239000002585 base Substances 0.000 description 85
- 239000000047 product Substances 0.000 description 47
- 235000018102 proteins Nutrition 0.000 description 36
- 239000000203 mixture Substances 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 23
- 108091035707 Consensus sequence Proteins 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- 108010054814 DNA Gyrase Proteins 0.000 description 19
- 229920000642 polymer Polymers 0.000 description 19
- 239000007795 chemical reaction product Substances 0.000 description 18
- 238000012546 transfer Methods 0.000 description 17
- 108060002716 Exonuclease Proteins 0.000 description 16
- 102000013165 exonuclease Human genes 0.000 description 16
- 238000001502 gel electrophoresis Methods 0.000 description 16
- 238000001179 sorption measurement Methods 0.000 description 14
- 108010017826 DNA Polymerase I Proteins 0.000 description 13
- 102000004594 DNA Polymerase I Human genes 0.000 description 13
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 12
- 239000000178 monomer Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 102000016559 DNA Primase Human genes 0.000 description 11
- 108010092681 DNA Primase Proteins 0.000 description 11
- 102000019196 RecQ Helicases Human genes 0.000 description 11
- 108010012737 RecQ Helicases Proteins 0.000 description 11
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 238000001042 affinity chromatography Methods 0.000 description 10
- 238000013467 fragmentation Methods 0.000 description 10
- 238000006062 fragmentation reaction Methods 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
- 244000063299 Bacillus subtilis Species 0.000 description 9
- 235000014469 Bacillus subtilis Nutrition 0.000 description 9
- 102000012410 DNA Ligases Human genes 0.000 description 9
- 108010061982 DNA Ligases Proteins 0.000 description 9
- 229910001413 alkali metal ion Inorganic materials 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 108060004795 Methyltransferase Proteins 0.000 description 8
- 101710093976 Plasmid-derived single-stranded DNA-binding protein Proteins 0.000 description 8
- 102000018120 Recombinases Human genes 0.000 description 8
- 108010091086 Recombinases Proteins 0.000 description 8
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 8
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 241000193830 Bacillus <bacterium> Species 0.000 description 7
- 108090000323 DNA Topoisomerases Proteins 0.000 description 7
- 102000003915 DNA Topoisomerases Human genes 0.000 description 7
- -1 NaAsp Chemical compound 0.000 description 7
- 239000003513 alkali Substances 0.000 description 7
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 7
- 238000002523 gelfiltration Methods 0.000 description 7
- 230000008676 import Effects 0.000 description 7
- 235000013919 monopotassium glutamate Nutrition 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 6
- 108010013829 alpha subunit DNA polymerase III Proteins 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 229910001425 magnesium ion Inorganic materials 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 150000003863 ammonium salts Chemical class 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241001515965 unidentified phage Species 0.000 description 5
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229950006238 nadide Drugs 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229950010342 uridine triphosphate Drugs 0.000 description 4
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 4
- 102000003844 DNA helicases Human genes 0.000 description 3
- 108090000133 DNA helicases Proteins 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 3
- 101710116602 DNA-Binding protein G5P Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010014594 Heterogeneous Nuclear Ribonucleoprotein A1 Proteins 0.000 description 3
- 101710162453 Replication factor A Proteins 0.000 description 3
- 101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 3
- 101710176276 SSB protein Proteins 0.000 description 3
- 241000235343 Saccharomycetales Species 0.000 description 3
- 241000589499 Thermus thermophilus Species 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 102200160559 rs104894505 Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- SMBXWJIRCAXTNE-UHFFFAOYSA-N 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]acetate hydrochloride Chemical compound Cl.OCC(CO)(CO)NCC(O)=O SMBXWJIRCAXTNE-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 101100045709 Aspergillus terreus (strain NIH 2624 / FGSC A1156) terG gene Proteins 0.000 description 2
- 101100045711 Aspergillus terreus (strain NIH 2624 / FGSC A1156) terI gene Proteins 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 101710135281 DNA polymerase III PolC-type Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 101150059304 hup gene Proteins 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 101150034433 terC gene Proteins 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 102000002281 Adenylate kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101100045712 Aspergillus terreus (strain NIH 2624 / FGSC A1156) terJ gene Proteins 0.000 description 1
- 101100400594 Azotobacter chroococcum mcd 1 hupL gene Proteins 0.000 description 1
- 101100508000 Azotobacter chroococcum mcd 1 hypB gene Proteins 0.000 description 1
- 101100011678 Bacteroides fragilis (strain YCH46) eno gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 101900063352 Escherichia coli DNA ligase Proteins 0.000 description 1
- 101900234631 Escherichia coli DNA polymerase I Proteins 0.000 description 1
- 101000587453 Escherichia coli Plasmid-derived single-stranded DNA-binding protein Proteins 0.000 description 1
- 101000587458 Escherichia coli Plasmid-derived single-stranded DNA-binding protein Proteins 0.000 description 1
- 101000700922 Escherichia coli Plasmid-derived single-stranded DNA-binding protein Proteins 0.000 description 1
- 101000826084 Escherichia coli Plasmid-derived single-stranded DNA-binding protein Proteins 0.000 description 1
- 101100028665 Escherichia coli parC gene Proteins 0.000 description 1
- 101100296413 Escherichia coli parE gene Proteins 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 101100070607 Haemophilus ducreyi (strain 35000HP / ATCC 700724) hgbA gene Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 101100029566 Rattus norvegicus Rabggta gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000005770 chromosome separation Effects 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108010055863 gene b exonuclease Proteins 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 101150043071 hupA gene Proteins 0.000 description 1
- 101150098043 hupB gene Proteins 0.000 description 1
- 101150081485 hypA gene Proteins 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229940068988 potassium aspartate Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- ZEDAGFBWUVYFQU-UHFFFAOYSA-M sodium;3-morpholin-4-ylpropane-1-sulfonate;hydrate Chemical compound [OH-].[Na+].OS(=O)(=O)CCCN1CCOCC1 ZEDAGFBWUVYFQU-UHFFFAOYSA-M 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 101150109832 tarJ gene Proteins 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/50—Other enzymatic activities
- C12Q2521/507—Recombinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2522/00—Reaction characterised by the use of non-enzymatic proteins
- C12Q2522/10—Nucleic acid binding proteins
- C12Q2522/101—Single or double stranded nucleic acid binding proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/125—Rolling circle
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cosmetics (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A kind of method that can be replicated in cell free system or expand cyclic DNA, particularly long-chain cyclic DNA is provided.Enzyme group below is being used specifically, providing: (1) being catalyzed the first enzyme group of the duplication of cyclic DNA;(2) the second enzyme group of 2 sisters' cyclic DNAs of catenane is reacted and is synthetically formed in the connection of catalysis Okazaki fragments;(3) duplication of third enzyme group or amplification for being catalyzed the separation reaction of 2 sisters' cyclic DNAs inhibit the generation of the DNA polymer as by-product method when having the cyclic DNA of replication initiation sequence (origin of chromosome (oriC)).In addition, also offer includes method the step of importing oriC into cyclic DNA using transposons.
Description
Technical field
The present invention relates to the duplication of cyclic DNA or amplification methods.More specifically, being related to can be in cell free system efficiently
The method of ground duplication or amplification cyclic DNA.The invention additionally relates to the functional box for being used to prepare cyclic DNA can be used as to utilize
Nucleic acid.
Background technique
The DNA clone technology on the basis as biotech development is the ring for making the cutting stickup by DNA fragmentation and preparing
The intracellular method that with plasmid form is expanded of the shape DNA in Escherichia coli etc..Expand using using the DNA clone technology of cell
When increasing cyclic DNA, the step that needs cell culture and the extraction of amplified production, purifying etc. loaded down with trivial details.In addition, in order to carry out using thin
The DNA clone of born of the same parents and need to make genetic recombination biology, therefore in terms of the environment that can be tested exist restrict.
As the method for DNA amplification in vitro, generally polymerase chain reaction (PCR) is used.But utilize PCR's
DNA cloning method can not directly expand cyclic DNA in test tube.As amplification in the test tube of cyclic DNA, there is rolling circle amplification
(RCA) etc. (non-patent literature 1, patent document 1, patent document 2, patent document 3).But in order to be expanded with rolling circle amplification
Cyclic DNA needs every secondary design to the primer of target dna specificity.In addition, the direct amplified production of rolling circle amplification is straight chain
Type DNA needs to carry out being incubated for etc. with recombinase further cyclisation process to be cyclized obtained amplified production.Also it reports
Road following methods: it after the microchromosome (oriC cyclic DNA) of duplication Escherichia coli, is isolated, obtains the ring of monomer
Shape replicates product (non-patent literature 2~5).But experiment is shown, under the reaction condition used in these documents, with ring-type
The duplicating efficiency of DNA molecular meter stops at the 15-40% or so of added template DNA, (non-to expand the unrealized multiplication of meter
Patent document 3~6).Further, the size of the cyclic DNA used in those references as template, which stops at, to be less than
10kbp。
To, in order to expand cyclic DNA with DNA cloning method in previous test tube, the combination of primer pair template DNA is needed,
Amplified production is straight chain type DNA, in addition, the DNA size that can be expanded stops at several kbp.In addition, wanting to use Escherichia coli small
Chromosome replication system is come the problem of when generating cricoid amplified production, having template cyclic DNA or even multiplication cannot be achieved.
Existing technical literature
Patent document
Patent document 1: Japanese Unexamined Patent Publication 2005-229950
Patent document 2: Japanese Unexamined Patent Publication 2008-161182
Patent document 3: Japanese Unexamined Patent Application Publication 2012-501173
Non-patent literature
Non-patent literature 1:Fakruddin M et al., J Pharm Bioallied Sci.2013,5:245-252
Non-patent literature 2:Peng H&Marians KJ.PNAS.1993,90:8571-8575
Non-patent literature 3:Hiasa H&Mar ians KJ.J Biol Chem.1994,269:32655-32659
Non-patent literature 4:Funnell B et al., J Biol Chem.1986,261:5616-5624
Non-patent literature 5:Hiasa H et al., J Biol Chem.1994,269:2093-2099
Non-patent literature 6:Hiasa H&Marians KJ.J Biol Chem.1994,269:26959-26968
Summary of the invention
Subject to be solved by the invention
The present invention provides the method that efficiently can replicate or expand cyclic DNA in cell free system.In addition the present invention mentions
For the nucleic acid that the functional box for being used to prepare cyclic DNA can be used as to utilize.
Means for solving the problems
Further investigation has been repeated in the inventors of the present invention in order to solve the above problems, as a result, it has been found that, using enzyme below
Group:
(1) it is catalyzed the first enzyme group of the duplication of cyclic DNA;
(2) the second enzyme group of 2 sisters' cyclic DNAs of catenane is reacted and is synthetically formed in the connection of catalysis Okazaki fragments;With
(3) the third enzyme group for being catalyzed the separation reaction of 2 sisters' cyclic DNAs has replication initiation sequence to replicate or expand
When the cyclic DNA of (origin of chromosome (oriC)), by using ter-Tus duplication terminate mechanism and/or
The DNA polymer separation mechanism of the site-specific recombination system of dif-XerCD etc. can inhibit the DNA polymer as by-product
Generation.In addition, it is found that by by oriC using transposons import cyclic DNA in, even if without oriC cyclic DNA only with
Also the duplication or amplification of cyclic DNA are able to carry out in the presence of low-down concentration.
In the present specification, the enzyme group duplication of above-mentioned (1), (2) and (3) or the reaction of amplification cyclic DNA will be used sometimes
It is denoted as RCR (replication-cycle reaction).
In addition, in the present specification, DNA polymer refers to: the generated polymer when replicating or expanding cyclic DNA
DNA (multimeric DNA).Here, the DNA of polymer refers to: using the cyclic DNA of template as monomer
(monomer) polymer occurs when capturing.In the present specification, DNA polymer is simply also denoted as " polymer " sometimes.
Though the application includes the invention of following manner that is, without being limited thereto.
[1] clone method of the cyclic DNA in a kind of cell free system, it includes processes below:
Process (1): being formed into the cyclic DNA of template and the reaction mixture of reaction solution, and the reaction solution includes following
Component:
First enzyme group of the duplication of catalysis cyclic DNA,
Catalysis Okazaki fragments connection reaction and be synthetically formed 2 sisters' cyclic DNAs of catenane second enzyme group and
It is catalyzed the third enzyme group of the separation reaction of 2 sisters' cyclic DNAs;With
Process (2): react the reaction mixture formed in process (1);
Here, the cyclic DNA include can with replication initiation sequence (the origin of in conjunction with the active enzyme of DnaA
Chromosome (oriC)) and also comprising being respectively relative to the 1 pair of ter sequence and/or DNA polymer that oriC is inserted into outward
The base sequence of enzyme identification is separated,
Here, in the case where the cyclic DNA has ter sequence, the reaction solution of foregoing sequence (1) also includes to have to combine
Inhibit the active protein of duplication in ter sequence, also, there is the alkali of DNA polymer separation enzyme identification in the cyclic DNA
In the case where basic sequence, the reaction solution of foregoing sequence (1) also includes DNA polymer separation enzyme.
[2] method according to above-mentioned [1], wherein it is Cre or XerCD that DNA polymer, which separates enzyme,.
[3] clone method of the cyclic DNA in a kind of cell free system, it includes processes below:
Process (1): being formed into the cyclic DNA of template and the reaction mixture of reaction solution, and the reaction solution includes following
Component:
First enzyme group of the duplication of catalysis cyclic DNA,
Catalysis Okazaki fragments connection reaction and be synthetically formed 2 sisters' cyclic DNAs of catenane second enzyme group and
It is catalyzed the third enzyme group of the separation reaction of 2 sisters' cyclic DNAs;With
Process (2): react the reaction mixture formed in process (1);
Here, the cyclic DNA include can with replication initiation sequence (the origin of in conjunction with the active enzyme of DnaA
Chromosome (oriC)) and also comprising being respectively relative to the 1 pair of ter sequence and/or XerCD identification that oriC is inserted into outward
Base sequence,
Here, in the case where the cyclic DNA has ter sequence, the reaction solution of foregoing sequence (1) also includes to have to combine
Inhibit the active protein of duplication in ter sequence, also, there are the feelings of the base sequence of XerCD identification in the cyclic DNA
Under condition, the reaction solution of foregoing sequence (1) also includes XerCD protein.
[4] method according to any one of above-mentioned [1] to [3], wherein be just respectively relative to what oriC was inserted into outward
1 for ter sequence, and the ter sequence as a side is in the 5 ' sides of oriC inserted with comprising in sequence shown in sequence number 1~14
Any sequence sequence, as another party ter sequence in the 3 ' sides of oriC inserted with including sequence shown in sequence number 1~14
The sequence of the complementary series of column.
[5] method according to any one of above-mentioned [1] to [4], wherein have and be incorporated into ter sequence and inhibit multiple
The active protein of system is Tus albumen or RTP albumen.
[6] method according to above-mentioned [2] or [3], wherein the base sequence of XerCD identification is to include sequence number 15
The sequence of any sequence in sequence shown in~24 or its complementary series.
[7] method according to above-mentioned [2], wherein the base sequence of Cre identification is comprising shown in sequence number 30~35
Sequence in any sequence sequence or its complementary series.
[8] a kind of nucleic acid comprising oriC and is respectively relative to for the linear DNA of the length with 273bp~2.0kb
The base sequence for 1 pair of ter sequence and/or DNA polymer the separation enzyme identification that oriC is inserted into outward.
[9] a kind of nucleic acid comprising oriC and is respectively relative to for the linear DNA of the length with 273bp~2.0kb
The base sequence for 1 pair of ter sequence and/or the XerCD identification that oriC is inserted into outward.
[10] clone method of the cyclic DNA in a kind of cell free system, it includes processes below:
Process (1): oriC transposons and transposase are added in buffer and form oriC swivel base body
(transposome), here, oriC transposons be comprising can with the replication initiation sequence in conjunction with the active enzyme of DnaA
The linear DNA of (origin of chromosome (oriC)) and for its two end include outer end (OE) sequence linear DNA;With
It reacts oriC swivel base body and the cyclic DNA without oriC in buffer, carries out transfer reaction;
Thus the cyclic DNA comprising oriC is prepared;
Process (2): the reaction mixture of cyclic DNA and reaction solution obtained in formation process (1) comprising oriC, it is described
Reaction solution includes following components:
First enzyme group of the duplication of catalysis cyclic DNA,
Catalysis Okazaki fragments connection reaction and be synthetically formed 2 sisters' cyclic DNAs of catenane second enzyme group and
It is catalyzed the third enzyme group of the separation reaction of 2 sisters' cyclic DNAs;With
Process (3): react the reaction mixture formed in process (2).
[11] method according to above-mentioned [10], wherein OE sequence includes sequence number 25 (5 '-
CTGTCTCTTATACACATCT-3 ') shown in sequence and its complementary series, process (1) linear DNA 5 ' ends be inserted into
There is the OE sequence comprising sequence shown in sequence number 25, in 3 ' ends of the linear DNA inserted with comprising shown in sequence number 25
The OE sequence of the complementary series of sequence.
[12] method according to above-mentioned [10] or [11] is comprising the cyclic DNA of oriC also includes opposite respectively
The base sequence of enzyme identification is separated in oriC 1 pair of ter sequence being inserted into outward and/or DNA polymer,
Here, in the case where the cyclic DNA has ter sequence, the reaction solution of foregoing sequence (2) also includes to have to combine
Inhibit the active protein of duplication in ter sequence, also, there is the alkali of DNA polymer separation enzyme identification in the cyclic DNA
In the case where basic sequence, the reaction solution of foregoing sequence (2) also includes DNA polymer separation enzyme.
[13] method according to above-mentioned [10] or [11] is comprising the cyclic DNA of oriC also includes opposite respectively
In the base sequence that oriC 1 pair of ter sequence being inserted into outward and/or XerCD are identified,
Here, in the case where the cyclic DNA has ter sequence, the reaction solution of foregoing sequence (2) also includes to have to combine
Inhibit the active protein of duplication in ter sequence, also, there are the feelings of the base sequence of XerCD identification in the cyclic DNA
Under condition, the reaction solution of foregoing sequence (2) also includes XerCD albumen.
[14] method according to any one of above-mentioned [10] to [13], wherein the oriC transposons of process (1) also wraps
Containing the base sequence for being respectively relative to 1 pair of ter sequence that oriC is inserted into outward and/or the separation enzyme identification of DNA polymer,
Here, in the case where the linear DNA has ter sequence, the reaction solution of foregoing sequence (2) also includes to have to combine
Inhibit the active protein of duplication in ter sequence, also, there is the alkali of DNA polymer separation enzyme identification in the cyclic DNA
In the case where basic sequence, the reaction solution of foregoing sequence (2) also includes DNA polymer separation enzyme.
[15] method according to any one of above-mentioned [10] to [13], wherein the oriC transposons of process (1) also wraps
Containing the base sequence for being respectively relative to 1 pair of ter sequence that oriC is inserted into outward and/or XerCD identification,
Here, in the case where the linear DNA has ter sequence, the reaction solution of foregoing sequence (2) also includes to have to combine
Inhibit the active protein of duplication in ter sequence, also, there are the feelings of the base sequence of XerCD identification in the cyclic DNA
Under condition, the reaction solution of foregoing sequence (2) also includes XerCD albumen.
[16] method according to any one of above-mentioned [10] to [15], wherein also include process (4): from process
(3) oriC transposons is removed in the cyclic DNA for replicating or expanding in reaction product.
[17] a kind of nucleic acid is comprising oriC and opposite respectively for the linear DNA of the length with 311bp~2.0kb
Include in oriC 1 pair of ter sequence being inserted into outward and/or the base sequence of DNA polymer separation enzyme identification, and in two ends
Outer end (OE) sequence.
[18] a kind of nucleic acid is comprising oriC and opposite respectively for the linear DNA of the length with 311bp~2.0kb
It include outer end (OE) sequence in the base sequence that oriC 1 pair of ter sequence being inserted into outward and/or XerCD identify, and in two ends
Column.
[19] the duplication kit of a kind of cyclic DNA, it includes the combinations of following components:
It is catalyzed the first enzyme group of the duplication of cyclic DNA;
The second enzyme group of 2 sisters' cyclic DNAs of catenane is reacted and is synthetically formed in catalysis Okazaki fragments connection;
It is catalyzed the third enzyme group of the separation reaction of 2 sisters' cyclic DNAs;
OriC transposons, here, oriC transposons be comprising can with the replication initiation in conjunction with the active enzyme of DnaA
The linear DNA of sequence (origin of chromosome (oriC)) and for its two end include outer end (OE) sequence threadiness
DNA;With
Transposase.
[20] kit according to above-mentioned [19], wherein oriC transposons also includes that be respectively relative to oriC outside
The base sequence of 1 pair of ter sequence and/or DNA polymer the separation enzyme identification of insertion.
[21] kit according to above-mentioned [20], wherein also comprising inhibiting duplication with ter sequence is incorporated into
Active protein;And/or DNA polymer separates enzyme.
[22] kit according to above-mentioned [19], wherein oriC transposons also includes that be respectively relative to oriC outside
The base sequence of 1 pair of ter sequence and/or the XerCD identification of insertion.
[23] kit according to above-mentioned [22], wherein also comprising inhibiting duplication with ter sequence is incorporated into
Active protein;And/or XerCD albumen.
The effect of invention
For the present processes, enzyme group below is being used:
(1) it is catalyzed the first enzyme group of the duplication of cyclic DNA;
(2) the second enzyme group of 2 sisters' cyclic DNAs of catenane is reacted and is synthetically formed in the connection of catalysis Okazaki fragments;With
(3) duplication of third enzyme group or amplification for being catalyzed the separation reaction of 2 sisters' cyclic DNAs have replication initiation sequence
When the cyclic DNA of (origin of chromosome (oriC)), the generation of the DNA polymer as by-product can inhibit.Separately
Outside, by importing in cyclic DNA oriC using transposons, the duplication or amplification of very low concentration of cyclic DNA are able to carry out.
For these reasons, duplication product or amplified production can be efficiently obtained using the present processes.
Detailed description of the invention
Fig. 1 shows the model of the replication cycle of cyclic DNA.
Fig. 2 is the skeleton diagram imported using the oriC box of transposons with duplication or amplified reaction hereafter.
Fig. 3 is to generate the skeleton diagram (a) inhibited using the DNA polymer of termination sequence ter and Tus albumen and show it
As a result gel electrophoresis images (b).
Fig. 4 be using locus specificity recombination sequence dif and XerCD DNA polymer generate inhibit skeleton diagram (a),
With the gel electrophoresis images (b) for showing its result.
Fig. 5 is the schematic diagram of 15kb-ori-ter cyclic DNA and 15kb-ori-dif cyclic DNA.
Fig. 6 is to generate to inhibit to show about the DNA polymer using termination sequence ter and Tus albumen to carry out Tus titration
As a result gel electrophoresis images.
Fig. 7 is to generate to inhibit to show about the DNA polymer using termination sequence ter and Tus albumen to carry out DNA titration
As a result gel electrophoresis images.
Fig. 8 is the gel electrophoresis images for showing DNA polymer caused by XerCD and generating the result inhibited.
Fig. 9 is the gel electrophoresis images for showing the amplification of the 15kb plasmid using the transfer of oriC transposons.
Figure 10 is the amplification for showing the 9.3kb plasmid of high GC containing ratio in the Thermophilic Bacteria source using the transfer of oriC transposons
As a result gel electrophoresis images.
Figure 11 is the gel electrophoresis images for showing the amplification of the 15kb plasmid using the transfer of oriC transposons.
Figure 12 be show change it is used in oriC transposons transfer reaction in the case where amount of DNA, utilize oriC to turn
The gel electrophoresis images of the amplification of the 15kb plasmid of stand transfer.
Figure 13 is the amplification for showing the 9.3kb plasmid of high GC containing ratio in the Thermophilic Bacteria source using the transfer of oriC transposons
As a result gel electrophoresis images.
Figure 14 is the amplification about the 9.3kb plasmid of the high GC containing ratio in the Thermophilic Bacteria source using the transfer of oriC transposons
Object shows the gel electrophoresis images for carrying out the result of limitation enzymic digestion (KpnI and NheI).
Figure 15 is the gel electrophoresis images for showing the result of cyclisation of research λ DNA.
Figure 16 is that the cyclisation for showing λ DNA and the gel electrophoresis of the amplification of the cyclic DNA after the transfer of oriC transposons are shone
Piece.
Figure 17 is that the amplified matter for the cyclic DNA that displaced about the cyclisation of λ DNA with oriC transposons shows carry out restriction enzyme
Digest the gel electrophoresis images of the result of (HindIII).
Figure 18 is the schematic diagram of the reaction that falls off of oriC transposons.
Figure 19 is the chart of oriC transposons of the evaluation comprising Km-oriC to fall off.
Figure 20 is the chart evaluated after oriC transposons falls off the Amp resistant gene of recovery.
Figure 21 be fall off reaction and the oriC transposons of oriC transposons based on cutting except dereaction schematic diagram.
Figure 22 is the gel electrophoresis images for showing DNA polymer caused by Cre and generating the result inhibited.
Specific embodiment
Next, being specifically illustrated to the present invention, but the present invention is not restricted to these.In the present specification, as long as not
Especially definition, then the scientific term used and technical term are associated in the present invention has containing for those skilled in the art's general understanding
Meaning.
< cyclic DNA >
The cyclic DNA used as template is preferably double-strand.As long as the cyclic DNA used as template is comprising can be with tool
The replication initiation sequence (origin of chromosome (oriC)) for having the active enzyme of DnaA to combine then is not particularly limited, can
It illustrates: the natural cyclic DNA such as circular chromosome of microorganism;Natural cyclic DNA is being obtained by the cutting such as enzymatic treatment
The upper other DNA fragmentation of connection such as substance, the cyclic DNA for being cyclized it;It is carried out at cyclisation to the naturally occurring DNA of straight-chain
Cyclic DNA made of reason;Completely artificial synthesized cyclic DNA etc..As can with the duplication in conjunction with the active enzyme of DnaA
Homing sequence (oriC) (hereinafter, being abbreviated as " replication initiation sequence " or " oriC " sometimes), can from NCBI (http: //
The public databases acquisition such as www.ncbi.nlm.nih.gov/) is present in the bacterium such as Escherichia coli, bacillus subtilis
Well known replication initiation sequence.In addition, by clone can with the DNA fragmentation in conjunction with the active enzyme of DnaA, to its base
Sequence is parsed, also available replication initiation sequence.
In the present invention, the cyclic DNA used as template can be cyclic DNA originally comprising replication initiation sequence,
It is also possible to import cyclic DNA made of replication initiation sequence to cyclic DNA of the script without replication initiation sequence.
About importing replication initiation sequence in the cyclic DNA for being free of replication initiation sequence to script, preparing makes as template
The method of cyclic DNA, using well known to a person skilled in the art methods.In a mode, replication initiation sequence is not to
Importing in the cyclic DNA of the sequence containing replication initiation can carry out as follows: by the transposons DNA comprising replication initiation sequence and turn
Seat enzyme be added in buffer and formed include replication initiation sequence swivel base body, make the swivel base body comprising replication initiation sequence with
Cyclic DNA without replication initiation sequence reacts in buffer, to carry out transfer reaction, wherein described comprising replicating
The transposons DNA of beginning sequence is the linear DNA comprising replication initiation sequence and its two end includes outer end (OE) sequence, 5 ' ends
The linear DNA being phosphorylated.
The cyclic DNA used in the present invention as template can include kanamycins, ampicillin, four according to purpose
Drug-resistance marker's gene order of ring element etc..
The cyclic DNA used in the present invention as template can be purified, and be also possible to the thallus comprising cyclic DNA and extracted
The form of the suspension of object etc..It, can also will such as DNA library etc furthermore it is possible to used using a kind of cyclic DNA as template
The mixtures of a variety of cyclic DNAs use in 1 test tube as template.
In the present invention, there is no limit can be set to such as 1kb (1000 alkali to the length of the cyclic DNA used as template
Base length) more than, 5kb (5000 bases longs) or more, 8kb (8,000 bases longs) or more, 10kb (10,000 bases longs)
Above, 50kb (50,000 bases longs) or more, 100kb (100,000 bases longs) or more, (200,000 bases are long by 200kb
Degree) more than, 500kb (500,000 bases longs) or more, 1000kb (1,000,000 bases longs) or more or 2000kb (2,
000,000 bases longs) more than length.
< the first, second, and third enzyme group >
1.First enzyme group
In the present specification, the first enzyme group refers to the enzyme group of the duplication of catalysis cyclic DNA.
First enzyme group of the duplication as catalysis cyclic DNA, can be used such as Kaguni JM&Kornberg
The enzyme group recorded in A.Cell.1984,38:183-90.Specifically, as the first enzyme group, can illustrate enzyme selected from the following or
Whole combinations of one or more of enzyme group or following enzyme or enzyme group: the nucleoid with the active enzyme of DnaA, a kind or more
Albumen has the active enzyme of DNA gyrase or enzyme group, single-stranded DNA binding protein (single-strand binding
Protein (SSB)), the enzyme with DnaB type helicase activity, with DNA helicase load the active enzyme of body, draw with DNA
The enzyme of enzymatic activity is sent out, active enzyme is pressed from both sides with DNA and there is the active enzyme of DNA polymerase i II* or enzyme group.
As with the active enzyme of DnaA, as long as having same as the DnaA of starting material albumen as Escherichia coli
Then its biological origin is not particularly limited the active enzyme of starting material, can be suitable for the DnaA using such as Escherichia coli.
The DnaA of Escherichia coli can include with the range of 1nM~10 μM in reaction solution in terms of monomer, preferably can be with 1nM
~~5 μM, 1nM~3 μM, 1nM~1.5 μM, 1nM~1.0 μM, 1nM~500nM, 50nM~200nM, 50nM~150nM model
It encloses include, but are not limited to this.
Nucleoid albumen refers to protein contained in nucleoid.1 kind or more of nucleoid albumen used in the present invention
As long as have with the same active enzyme of the nucleoid albumen of Escherichia coli, then its biological origin is not particularly limited, can
To be suitable for complex (heterodimer or homologous dimerization using IHF, i.e. IhfA and/or the IhfB of such as Escherichia coli
Body) or the HU of Escherichia coli, i.e. hupA and hupB complex.The IHF of Escherichia coli is with heterologous/homodimer
Meter can include with the range of 5nM~400nM in reaction solution, preferably can be with 5nM~200nM, 5nM~100nM, 5nM
~50nM, 10nM~50nM, 10nM~40nM, 10nM~30nM range include, but are not limited to this.Escherichia coli
HU can include that can preferably be come with the range of 5nM~50nM, 5nM~25nM with the range of 1nM~50nM in reaction solution
It include, but are not limited to this.
As with the active enzyme of DNA gyrase or enzyme group, as long as having same as the DNA gyrase of Escherichia coli
Active enzyme, then its biological origin is not particularly limited, and can be suitable for GyrA and GyrB using such as Escherichia coli
It is formed by complex.The GyrA and GyrB of Escherichia coli are formed by complex in terms of the heterologous tetramer in reaction solution
Can include with the range of 20nM~500nM, preferably can with 20nM~400nM, 20nM~300nM, 20nM~200nM,
50nM~200nM, 100nM~200nM range include, but are not limited to this.
As single-stranded DNA binding protein (single-strand binding protein (SSB)), as long as have with
The same active enzyme of the single-stranded DNA binding protein of Escherichia coli, then its biological origin is not particularly limited, and can be suitable for making
With the SSB of such as Escherichia coli.The SSB of Escherichia coli in terms of homotetramer in reaction solution can with 20nM~
The range of 1000nM includes, preferably can with 20nM~500nM, 20nM~300nM, 20nM~200nM, 50nM~500nM,
The model of 50nM~400nM, 50nM~300nM, 50nM~200nM, 50nM~150nM, 100nM~500nM, 100nM~400nM
It encloses include, but are not limited to this.
As the enzyme with DnaB type helicase activity, as long as having similarly active with the DnaB of Escherichia coli
Enzyme, then its biological origin is not particularly limited, and can be suitable for the DnaB using such as Escherichia coli.Escherichia coli
DnaB can include with the range of 5nM~200nM in reaction solution in terms of homo-hexamer, preferably can with 5nM~
100nM, 5nM~50nM, 5nM~30nM range include, but are not limited to this.
The active enzyme of body is loaded as with DNA helicase, as long as having similarly active with the DnaC of Escherichia coli
Enzyme, then its biological origin is not particularly limited, and can be suitable for the DnaC using such as Escherichia coli.Escherichia coli come
The DnaC in source can include with the range of 5nM~200nM in reaction solution in terms of homo-hexamer, preferably can with 5nM~
100nM, 5nM~50nM, 5nM~30nM range include, but are not limited to this.
As with the active enzyme of DNA primase, as long as have with the same active enzyme of the DnaG of Escherichia coli, then
Its biological origin is not particularly limited, and can be suitable for the DnaG using such as Escherichia coli.Escherichia coli
DnaG can include with the range of 20nM~1000nM in reaction solution in terms of monomer, preferably can with 20nM~800nM,
50nM~800nM, 100nM~800nM, 200nM~800nM, 250nM~800nM, 250nM~500nM, 300nM~500nM
Range include, but are not limited to this.
Press from both sides active enzyme as with DNA, as long as have with the same active enzyme of the DnaN of Escherichia coli, then it is given birth to
Object source is not particularly limited, and can be suitable for the DnaN using such as Escherichia coli.The DnaN of Escherichia coli with
Homodimer meter can include with the range of 10nM~1000nM in reaction solution, preferably can with 10nM~800nM,
10nM~500nM, 20nM~500nM, 20nM~200nM, 30nM~200nM, 30nM~100nM range include, but not
It is limited to this.
As with the active enzyme of DNA polymerase i II* or enzyme group, as long as having the archaeal dna polymerase with Escherichia coli
III* complex similarly active enzyme or enzyme group, then its biological origin is not particularly limited, and can be suitable for using for example wrapping
The enzyme group of any one of DnaX, HolA, HolB, HolC, HolD, DnaE, DnaQ and HolE containing Escherichia coli, it is excellent
It is selected as the enzyme group of the complex of DnaX, HolA, HolB and DnaE comprising Escherichia coli, further preferably comprising big
The enzyme group of the complex of DnaX, HolA, HolB, HolC, HolD, DnaE, DnaQ and the HolE in enterobacteria source.Escherichia coli
The DNA polymerase i II* complex in source can include with the range of 2nM~50nM in reaction solution in terms of heteromultimers,
It is preferred that can be come with the range of 2nM~40nM, 2nM~30nM, 2nM~20nM, 5nM~40nM, 5nM~30nM, 5nM~20nM
It include, but are not limited to this.
2.Second enzyme group
In the present specification, second enzyme group refers to that 2 elder sisters of catenane are reacted and are synthetically formed in catalysis Okazaki fragments connection
The enzyme group of younger sister's cyclic DNA.
In the present invention, 2 sisters' cyclic DNAs for forming catenane refer to 2 ring-types synthesized by DNA replication dna reaction
DNA is in the cyclic DNA of connection status.
The second enzyme group of 2 sisters' cyclic DNAs of catenane is synthetically formed as catalysis Okazaki fragments connection reaction, it can
With illustrate for example selected from by with the active enzyme of DNA polymerase i, there is the active enzyme of DNA ligase and have RNaseH active
Enzyme composition one or more of group enzyme or the enzyme combination.
As with the active enzyme of DNA polymerase i, as long as having with the DNA polymerase i of Escherichia coli as long as same activity
Its biological origin is not particularly limited, and can be suitable for the DNA polymerase i using such as Escherichia coli.Escherichia coli come
The DNA polymerase i in source can include with the range of 10nM~200nM in reaction solution in terms of monomer, preferably can be with 20nM
~200nM, 20nM~150nM, 20nM~100nM, 40nM~150nM, 40nM~100nM, 40nM~80nM range is wrapped
Contain, but not limited to this.
As with the active enzyme of DNA ligase, as long as having with the DNA ligase of Escherichia coli as long as same activity it
Biological origin is not particularly limited, and can be suitable for the DNA of the DNA ligase or T4 bacteriophage using such as Escherichia coli
Ligase.The DNA ligase of Escherichia coli can be wrapped in terms of monomer in reaction solution with the range of 10nM~200nM
Contain, it preferably can be with the range of 15nM~200nM, 20nM~200nM, 20nM~150nM, 20nM~100nM, 20nM~80nM
Include, but are not limited to this.
As with the active enzyme of RNaseH, it is given birth to as long as having the activity for decomposing the RNA chain of RNA:DNA hybrid
Object source is not particularly limited, and can be suitable for the RNaseH using such as Escherichia coli.Escherichia coli
RNaseH can include with the range of 0.2nM~200nM in reaction solution in terms of monomer, preferably can with 0.2nM~
200nM, 0.2nM~100nM, 0.2nM~50nM, 1nM~200nM, 1nM~100nM, 1nM~50nM, 10nM~50nM model
It encloses include, but are not limited to this.
3.Third enzyme group
In the present specification, third enzyme group refers to the enzyme group of the separation reaction of 2 sisters' cyclic DNAs of catalysis.
The third enzyme group of separation reaction as 2 sisters' cyclic DNAs of catalysis, can be used such as Peng H&Marians
The enzyme group recorded in KJ.PNAS.1993,90:8571-8575.Specifically, selected from the following 1 can be illustrated as third enzyme group
Kind or more enzyme or the enzyme combination: with the active enzyme of topoisomerase I V, have the active enzyme of topoisomerase II I and
Enzyme with RecQ type helicase activity.
As with the active enzyme of topoisomerase II I, as long as having same as the topoisomerase II I of Escherichia coli
Active then its biological origin is not particularly limited, and can be suitable for the topoisomerase II I using such as Escherichia coli.Greatly
The topoisomerase II I in enterobacteria source can include with the range of 20nM~500nM in reaction solution in terms of monomer, preferably
Can include with the range of 20nM~400nM, 20nM~300nM, 20nM~200nM, 20nM~100nM, 30~80nM, but
It is without being limited thereto.
As the enzyme with RecQ type helicase activity, as long as have with the RecQ of Escherichia coli same activity then its
Biological origin is not particularly limited, and can be suitable for the RecQ using such as Escherichia coli.The RecQ of Escherichia coli
Can include with the range of 20nM~500nM in reaction solution in terms of monomer, preferably can with 20nM~400nM, 20nM~
300nM, 20nM~200nM, 20nM~100nM, 30~80nM range include, but are not limited to this.
As with the active enzyme of topoisomerase I V, similarly live as long as having with the topoisomerase I V of Escherichia coli
Then its biological origin is not particularly limited property, can be suitable for using for example as the Escherichia coli of the complex of ParC and ParE
The topoisomerase I V in source.The topoisomerase I V of Escherichia coli can be in reaction solution in terms of the heterologous tetramer
The range of 0.1nM~50nMM includes, preferably can with 0.1nM~40nM, 0.1nM~30nM, 0.1nM~20nM, 1nM~
40nM, 1nM~30nM, 1nM~20nM, 1nM~10nM, 1nM~5nM range include, but are not limited to this.
Commercially available product can be used in the first, second, and third above-mentioned enzyme group, also can be used from the extractions such as microorganism and basis
The enzyme group for needing to purify.Enzyme from microorganism extraction and purifying that method that those skilled in the art can utilize can be used is suitable
Preferably implement.
Enzyme other than the enzyme of Escherichia coli shown in stating in use is as above-mentioned first, second, and third enzyme group
When, it can be relative to the concentration range that the enzyme for above-mentioned Escherichia coli determines according to comparable dense in terms of unit of enzyme activity
Degree range come using.
The reaction solution of the cell-free protein expression system containing above-mentioned enzyme can also be made directly to mix with the cyclic DNA for becoming template
Close and formed the reaction mixture of duplication or the amplification for cyclic DNA.Cell-free protein expression system can be with containing by
With total serum IgE (total RNA), mRNA or the in of the RNA of the Sequence composition of the base sequence complementary for the gene for encoding above-mentioned enzyme
Vitro transcription product etc. is united as the cell free translation system of template ribonucleic acid, is also possible to encode the gene of each enzyme or containing coding
The cell-free transcription translation system as template DNA such as expression vector of the gene of each enzyme.
Clone method (A) > of < cyclic DNA
In a mode, this application involves the duplications of the cyclic DNA in cell free system or amplification method (hereinafter, at this
Sometimes " method (A) " is denoted as in specification), it includes processes below:
Process (1): being formed into the cyclic DNA of template and the reaction mixture of reaction solution, and the reaction solution includes following
Component:
First enzyme group of the duplication of catalysis cyclic DNA,
Catalysis Okazaki fragments connection reaction and be synthetically formed 2 sisters' cyclic DNAs of catenane second enzyme group and
It is catalyzed the third enzyme group of the separation reaction of 2 sisters' cyclic DNAs;With
Process (2): react the reaction mixture formed in process (1);
Here, the cyclic DNA include can with replication initiation sequence (the origin of in conjunction with the active enzyme of DnaA
Chromosome (oriC)) and also comprising being respectively relative to the 1 pair of ter sequence and/or XerCD identification that oriC is inserted into outward
Base sequence,
Here, in the case where the cyclic DNA has ter sequence, the reaction solution of foregoing sequence (1) also includes to have to combine
Inhibit the active protein of duplication in ter sequence, also, there are the feelings of the base sequence of XerCD identification in the cyclic DNA
Under condition, the reaction solution of foregoing sequence (1) also includes XerCD albumen.
Although being not limited by theory, method (A) is by replication cycle shown in FIG. 1 or repeats the duplication
It recycles and replicates or expand cyclic DNA.In the present specification, duplication cyclic DNA refers to: generating and the cyclic DNA as template
Identical molecule.When the duplication of cyclic DNA can be started by the cyclic DNA amount in the reaction product after reaction relative to reaction
The cyclic DNA amount as template increase this point and confirm.Preferably, the duplication of cyclic DNA refers to: starting relative to reaction
When cyclic DNA amount, the cyclic DNA amount in reaction product increases at least 2 times, 3 times, 5 times, 7 times, 9 times.Expand cyclic DNA
Refer to: the duplication of cyclic DNA promotes, the ring as template when the amount of the cyclic DNA in reaction product starts relative to reaction
Shape amount of DNA increases according to index rank.Therefore, the amplification of cyclic DNA is a kind of mode of the duplication of cyclic DNA.In this explanation
In book, the amplification of cyclic DNA refers to: the cyclic DNA amount as template when starting relative to reaction, the ring-type in reaction product
Amount of DNA increases at least 10 times, 50 times, 100 times, 200 times, 500 times, 1000 times, 2000 times, 3000 times, 4000 times, 5000 times
Or 10000 times.
In the present processes, " cell free system " refers to not intracellular replication reaction.That is, using cell free system
The present processes of implementation are to carry out in vitro.It is also the same in " method (B) " recorded below.
It is recorded in such as project of above-mentioned < cyclic DNA > about the cyclic DNA mixed with reaction solution.Make in every 1 reaction
The amount of template DNA is not particularly limited, for example, react start when can with 10ng/ μ l or less, 5ng/ μ l or less,
1ng/ μ l or less, 0.8ng/ μ l or less, 0.5ng/ μ l or less, 0.1ng/ μ l or less, 50pg/ μ l or less, 5pg/ μ l or less,
0.5pg/ μ l or less, 50fg/ μ l or less, 5fg/ μ l or less, 0.5fg/ μ l concentration below are present in reaction solution.Further
It ground can also there are the cyclic DNAs of 1 molecule as template is used to replicate or expand using every 1 reaction when reaction starts.
As the cyclic DNA of template comprising being respectively relative to 1 pair of ter sequence that oriC is inserted into outward used in method (A)
Column and/or the base sequence of XerCD identification.In the case where the cyclic DNA has ter sequence, the reaction solution of process (1) is also wrapped
Containing have be incorporated into ter sequence and inhibit duplication active protein, also, the cyclic DNA have XerCD identification alkali
In the case where basic sequence, the reaction solution of process (1) also includes XerCD albumen.
Inhibit the active protein of duplication and/or XerCD that commercially available product can be used with ter sequence is incorporated into,
The protein extracted from microorganism etc. simultaneously as needed after purification can be used.Enzyme from microorganism extraction and purifying can be with
Suitably implemented using the method that those skilled in the art can utilize.
Ter sequence on DNA and the group of the active protein of duplication is inhibited to be combined into progress with ter sequence is incorporated into
Replicate the mechanism of termination.The mechanism is found in various bacteria, for example, it is known in Escherichia coli for Tus-ter system (Hiasa,
H.,and Marians,K.J.,J.Biol.Chem.,1994,269:26959-26968;Neylon,C.,et al.,
Microbiol.Mol.Biol.Rev., 2005 September, p.501-526), it is RTP-ter in bacillus
System (Vivian, et al., J.Mol.Biol., 2007,370:481-491).It, should by utilizing in the present processes
Mechanism is able to suppress the generation of the DNA polymer as by-product.About on DNA ter sequence and have be incorporated into ter sequence
The combination of column and the active protein of inhibition duplication, biological origin are not particularly limited.
In preferred embodiment, the present processes use the combination of ter sequence and Tus albumen.In combination with Tus albumen
The ter sequence used can be comprising 5 '-GN [A/G] [T/A] GTTGTAAC [T/G] A-3 ' (sequence number 1), more preferably 5 '-G
[T/G] A [T/A] GTTGTAAC [T/G] A-3 ' (sequence number 2), 5 '-GTATGTTGTAACTA-3 ' (sequence number 3), 5 '-
AGTATGTTGTAACTAAAG-3 ' (sequence number 4), 5 '-GGATGTTGTAACTA-3 ' (sequence number 5), 5 '-
GTATGTTGTAACGA-3 ' (sequence number 6), 5 '-GGATGTTGTAACTA-3 ' (sequence number 7), 5 '-GGAAGTTGTAACGA-3 '
The sequence of (sequence number 8) or 5 '-GTAAGTTGTAACGA-3 ' (sequence number 9).The source of Tus albumen is not particularly limited, excellent
It is selected as the Tus albumen of Escherichia coli.Tus albumen can include with the range of 1nM~200nM in reaction solution, preferably
Can with 2nM~200nM, 2nM~100nM, 5nM~200nM, 5nM~100nM, 10nM~100nM, 20nM~100nM,
The range of 20nM~80nM include, but are not limited to this.
In another preferred embodiment, the present processes use the combination of ter sequence and RTP albumen.With the group of RTP albumen
Ter sequence used in conjunction is comprising 5 '-AC [T/A] [A/G] ANNNNN [C/T] NATGTACNAAAT-3 ' (sequence number 10), excellent
It is selected as 5 '-ACTAATT [A/G] A [A/T] C [T/C] ATGTACTAAAT-3 ' (sequence number 11), 5 '-ACTAATT [A/G] A [A/T]
C [T/C] ATGTACTAAATTTTCA-3 ' (sequence number 12), 5 '-GAACTAATTAAACTATGTACTAAATTTTCA-3 ' (sequence
Or the sequence of 23~30 bases longs of 5 '-ATACTAATTGATCCATGTACTAAATTTTCA-3 ' (sequence number 14) number 13).
As ter sequence, when selection includes the sequence of sequence number 10~12 and has the sequence of 23~30 bases longs, the sequence phase
It can have at least 70%, at least 80%, at least 90%, at least 95% sequence identity for sequence number 13 or 14.RTP egg
White source is not particularly limited, preferably the RTP albumen in bacillus source, more preferably bacillus subtilis
The RTP albumen in the source (Bacillus subtilis).Tus albumen can be wrapped in reaction solution with the range of 1nM~200nM
Contain, preferably can with 2nM~200nM, 2nM~100nM, 5nM~200nM, 5nM~100nM, 10nM~100nM, 20nM~
100nM, 20nM~80nM range include, but are not limited to this.About ter sequence, " being inserted into outward relative to oriC " refers to:
Have be incorporated into ter sequence and inhibit duplication active protein compound action under, for from oriC towards outside
The duplication in direction allow to be replicated, and the duplication in the direction for entering to oriC does not allow then to replicate and stops carrying out
Ter sequence is inserted into direction.The arrow of ter sequence in (a) of Fig. 3 and Fig. 5 show 1 pair of ter sequence be respectively relative to oriC by
According to the state of outwardly direction insertion.Accordingly, with respect to ter sequence, " being respectively relative to 1 pair that oriC is inserted into outward " refers to: one
Side is in the 5 ' sides of oriC inserted with the sequence comprising any sequence in sequence shown in sequence number 1~14, another party in oriC
Sequence of the 3 ' sides inserted with the complementary series comprising sequence shown in sequence number 1~14 state.
For ter sequence, as long as relative to oriC 1 pair of insertion outward respectively, so that it may be present in any position.Example
Such as, 1 pair of ter sequence can reside in the region for becoming opposite side (Japanese: to pole To な Ru) relative to oriC, there may also be
Near the two sides oriC or adjacent region.It, can be by oriC when being present in region near the two sides oriC or adjacent
Functional box is made with 1 pair of ter sequence, therefore importing of oriC and 1 pair of ter sequence to DNA becomes easy, having becomes template
Cyclic DNA preparation cost reduce the advantages of.
The sequence of XerCD identification and the group of XerCD albumen on DNA are combined into the isolated mechanism for carrying out DNA polymer
(Ip,S.C.Y.,et al.,EMBO J.,2003,22:6399-6407).XerCD albumen is the complex of XerC and XerD.Make
The sequence identified by XerCD albumen, it is known to dif sequence, cer sequence, psi sequence (Colloms, et al., EMBO J.,
1996,15(5):1172-1181;Arciszewska,L.K.,et al.,J.Mol.Biol.,2000,299:391-403).In
In the present processes, by utilizing the mechanism, it is able to suppress the generation of the DNA polymer as by-product.About on DNA
The sequence of XerCD identification and the combination of XerCD albumen, biological origin are not particularly limited.In addition, for XerCD,
Its promotive factor be it is known, such as FtsK albumen can promote dif function (Ip, S.C.Y., et al., EMBO J., 2003,
22:6399-6407).In a mode, FtsK albumen may include in the reaction solution of the application method.
The sequence of XerCD identification can be comprising 5 '-GGTGCG [C/T] [A/G] [T/C] AANNNNNNTTATG [T/G]
TAAA [T/C] -3 ' (sequence number 15), 5 '-GGTGCG [C/T] A [T/C] AANNNNNNTTATG [T/G] TAAAT-3 ' (sequence number
16), 5 '-GGTGCGC [A/G] [T/C] AANNNNNNTTATGTTAAA [T/C] -3 ' (sequence number 17), 5 '-GGTGCG [C/T]
[A/G] CAANNNNNNTTATG [T/G] TAAA [T/C] -3 ' (sequence number 18), 5 ' -
GGTGCGCATAANNNNNNTTATGTTAAAT-3 ' (sequence number 19), 5 '-GGTGCGTACAANNNNNNTTATGGTAAAT-3 '
(sequence number 20), 5 '-GGTGCGCGCAANNNNNNTTATGTTAAAC-3 ' (sequence number 21), 5 '-
GGTGCGCATAATGTATATTATGTTAAAT-3 ' (sequence number 22/dif sequence), 5 '-
GGTGCGTACAAGGGATGTTATGGTAAAT-3 ' (sequence number 23/cer sequence) or 5 '-
The complementary series of GGTGCGCGCAAGATCCATTATGTTAAAC-3 ' (sequence number 24/psi sequence) or either of which person
Sequence.1st~11 base portion of sequence number 15~24 be XerC binding site, the 18th~28 of sequence number 15~24 the
The base portion of position is XerD binding site.12nd~17 base portion (6 alkali shown in NNNNNN of sequence number 15~21
Base portion point) be not XerC or XerD bond area, therefore sequence is not particularly limited.Preferably, sequence number 15~21
12nd~17 alkali of 12nd~17 base (6 base portion shown in the NNNNNN) sequence relative to sequence number 22~24
Basic sequence can have at least 70%, at least 80%, at least 90%, at least 95% sequence identity.
XerCD albumen is preferably the XerCD albumen of Escherichia coli.XerCD albumen in reaction solution can with 1nM~
The range of 200nM includes, preferably can with 5nM~200nM, 5nM~150nM, 10nM~200nM, 10nM~150nM,
20nM~200nM, 20nM~150nM, 20nM~100nM range include, but are not limited to this.
The sequence of XerCD identification can reside in any position on cyclic DNA.Such as the sequence of XerCD identification can be with
It is present in the region for becoming opposite side relative to oriC, can also exist on region near oriC or adjacent.When being present in
Near oriC or when adjacent region, functional box can be made by oriC and by the XerCD sequence identified, thus oriC and
Importing by from the sequence of XerCD identification to DNA becomes easy, there is the preparation cost of the cyclic DNA as template to reduce excellent
Point.
In this specification, the consistency % of 2 base sequences, which can be checked by visual observation with mathematical computations, to be determined.Separately
Outside, consistency % can also be determined using computer program.Compare computer program as this kind of sequence, it can be mentioned, for example can
With from the website of U.S. national library of medicine: http://www.ncbi.nlm.nih.gov/blast/bl2seq/
The BLASTN program (Altschul et al. (1990) J.Mol.Biol.215:403-10) utilized in bls.html: version number
Or WU-BLAST2.0 algorithm etc. 2.2.7.The setting of standardized default parameter about WU-BLAST2.0 can be used with off line
It stands: the parameter recorded in http://blast.wustl.edu.
The first, second, and third enzyme group contained in reaction solution, according to above-mentioned < the first, second, and third enzyme group >
Project in record.
In some mode, the first enzyme group used in the present processes may include the combination of following enzymes or enzyme group:
With the active enzyme of DnaA, a kind or more of nucleoid albumen, there is the active enzyme of DNA gyrase or enzyme group, single stranded DNA to combine
Albumen (single-strand binding protein (SSB)), the enzyme with DnaB type helicase activity untwist with DNA
Enzyme loads the active enzyme of body, active enzyme is pressed from both sides with the active enzyme of DNA primase, with DNA and has DNA polymerase i II*
Active enzyme or enzyme group.Here, a kind or more of nucleoid albumen can be IHF or HU, have the active enzyme of DNA gyrase or
Enzyme group can be GyrA and GyrB is formed by complex, and the enzyme with DnaB type helicase activity can be DnaB unwindase,
Loading the active enzyme of body with DNA helicase can be DnaC unwindase loading body, and there is the active enzyme of DNA primase can be
DnaG primase, there is DNA, which to press from both sides active enzyme, can be DnaN folder, also, have the active enzyme of DNA polymerase i II* or enzyme group
It can be enzyme or enzyme group comprising any one of DnaX, HolA, HolB, HolC, HolD, DnaE, DnaQ and HolE.
In other mode, second enzyme group used in method of the invention be may include with DNA polymerase i activity
Enzyme and combination with the active enzyme of DNA ligase.Alternatively, second enzyme group may include it is active with DNA polymerase i
Enzyme, the combination with the active enzyme of DNA ligase and with the active enzyme of RNaseH.
In another mode, third enzyme group used in the present processes may include living with topoisomerase II I
Property enzyme and/or have the active enzyme of topoisomerase I V.It lives alternatively, third enzyme group may include with topoisomerase II I
The combination of the enzyme and the enzyme with RecQ type helicase activity of property.Alternatively, in addition third enzyme group can be with topoisomerase
The active enzyme of III, the enzyme with RecQ type helicase activity and the combination with the active enzyme of topoisomerase I V.
Reaction solution may include buffer, ATP, GTP, CTP, UTP, dNTP, magnesium ion source and alkali metal ion source.
As long as the buffering that buffer contained in reaction solution is suitable for for the use under pH7~9, preferably pH8
Liquid is then not particularly limited.It can be mentioned, for example Tris-HCl, Hepes-KOH, phosphate buffer, MOPS-NaOH, Tricine-
HCl etc..Preferred buffer is Tris-HCl.The concentration of buffer can suitably be selected by those skilled in the art, without spy
It does not limit, in the case where Tris-HCl, can choose the concentration of such as 10mM~100mM, 10mM~50mM, 20mM.
ATP refers to adenosine triphosphate.When reacting beginning, the concentration of ATP contained in reaction solution can be such as 0.1mM
The range of~3mM can also be preferably the range of 0.1mM~2mM, 0.1mM~1.5mM, 0.5mM~1.5mM.
GTP, CTP and UTP each refer to guanosine triphosphate, cytidine triphosphate (CTP) and uridine triphosphate.It is anti-when reacting beginning
Answer the concentration of GTP, CTP and UTP contained in liquid that can be each independently the range of such as 0.1mM~3.0mM, it can also be preferred
For the range of 0.5mM~3.0mM, 0.5mM~2.0mM.
DNTP be deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate (dGTP), deoxycytidine triphosphate (dCTP),
With the general name of deoxythymidine triphosphoric acid (dTTP).When reacting beginning, the concentration of dNTP contained in reaction solution can be example
It can also be preferably the range of 0.05mM~1mM, 0.1mM~1mM such as the range of 0.01~1mM.
Magnesium ion source is the offer magnesium ion (Mg into reaction solution2+) substance.It can be mentioned, for example Mg (OAc)2、MgCl2And
MgSO4Deng.Preferred magnesium ion source is Mg (OAc)2.React start when reaction solution contained in the concentration of magnesium ion source can be with
It is to provide the concentration of magnesium ion for example in reaction solution with the range of 5~50mM.
Alkali metal ion source is the substance that alkali metal ion is given into reaction solution.As alkali metal ion, example can be enumerated
Such as sodium ion (Na+), potassium ion (K+).As the example in alkali metal ion source, potassium glutamate, potassium aspartate, chlorination can be enumerated
Potassium, potassium acetate, sodium glutamate, NaAsp, sodium chloride and sodium acetate.Preferred alkali metal ion source is potassium glutamate.In
The concentration in alkali metal ion source contained in reaction solution can be mentioned in reaction solution with the range of 100mM~300mM when reaction starts
For the concentration of alkali metal ion, but not limited to this.It, can also be from above-mentioned alkali metal ion in order to be consistent with first application
150mM is excluded in the concentration in source.
Reaction solution can also include the non-specific adsorption inhibitor of protein or the non-specific adsorption inhibitor of nucleic acid.
Preferably, reaction solution can also include the non-specific adsorption inhibitor of protein and the non-specific adsorption inhibitor of nucleic acid.
It is present in reaction solution by the non-specific adsorption inhibitor and/or the non-specific adsorption inhibitor of nucleic acid that make protein,
It can inhibit protein each other and/or non-specific adsorption, protein and the cyclic DNA of protein and cyclic DNA are to container table
The attachment in face can expect that reaction efficiency improves.
The non-specific adsorption inhibitor of protein refer to in the present processes duplication or amplified reaction it is unrelated
Protein.As such protein, it can be mentioned, for example bovine serum albumin(BSA) (BSA), lysozyme, gelatin, heparin and caseins
Deng.The non-specific adsorption inhibitor of protein can in reaction solution with the range of 0.02~2.0mg/ml, preferably 0.1~
2.0mg/ml, 0.2~2.0mg/ml, 0.5~2.0mg/ml range include, but are not limited to this.
The non-specific adsorption inhibitor of nucleic acid refer to in the present processes duplication or the unrelated core of amplified reaction
Acid molecule or nucleic acid are similar to the factor.As such nucleic acid molecules or nucleic acid similar to the factor, it can be mentioned, for example tRNA (transhipments
RNA), rRNA (rRNA), mRNA (mRNA), glycogen, heparin, widow DNA, poly (I-C) (the poly- cytidine of polyinosine -),
Poly (dI-dC) (the poly- poly- deoxycytidine of deoxyinosine -), poly (A) (poly- adenine) and poly (dA) (poly- deoxyadenine)
Deng.The non-specific adsorption inhibitor of nucleic acid can be in reaction solution with the range of 1~500ng/ μ l, preferably 10~500ng/ μ
L, 10~200ng/ μ l, 10~100ng/ μ l range include, but are not limited to this.In order to be taken into account with first application, select
When selecting non-specific adsorption inhibitor of the tRNA as nucleic acid, 50ng/ μ l can be excluded from the concentration of tRNA.
Reaction solution can also include straight-chain DNA specificity exonuclease or RecG type unwindase.Preferably, reaction solution
It can also include straight-chain DNA specificity exonuclease and RecG type unwindase.By making the circumscribed core of straight-chain DNA specificity
Sour enzyme and/or RecG type unwindase are present in reaction solution.Can reduce in duplication or amplified reaction due to double-strand cutting etc. and
The amount of the straight-chain DNA of generation can expect the raising of the yield of target supercoil product.
Straight-chain DNA specificity exonuclease is successively hydrolyzed from the 5 ' ends of straight-chain DNA or 3 ' ends
Enzyme.It is successively hydrolyzed as long as straight-chain DNA specificity exonuclease has from the 5 ' ends of straight-chain DNA or 3 ' ends
Active then its type or biological origin are not particularly limited.For example, RecBCD, λ exonuclease, exonuclease can be used
III, exonuclease VIII, T5 exonuclease, T7 exonuclease and Plasmid-SafeTM ATP-Dependent
DNA enzymatic (epicentre) etc..Preferred straight-chain DNA specificity exonuclease is RecBCD.Straight-chain DNA exonuclease
Enzyme can be include, but are not limited in reaction solution with the range of the range of 0.01~1.0U/ μ l, preferably 0.1~1.0U/ μ l
This.It is to make straight-chain in the reaction of 37 DEG C, 30 minutes about the unit of enzyme activity (U) of straight-chain DNA exonuclease
Unit of the enzyme amount as 1U needed for the deoxyribonucleotide of the 1nmol of DNA becomes acid-solubility.
RecG type unwindase is considered as the second level DNA removed when extension terminates by replication fork is impinging one another and is formed
The enzyme of the unwindase of structure.RecG type unwindase its biology as long as having with the RecG of Escherichia coli similarly activity
Source is not particularly limited, and can be suitable for the RecG using such as Escherichia coli.The RecG of Escherichia coli is with monomer
Meter in reaction solution can with the range of 100nM~800nM, preferably 100nM~500nM, 100nM~400nM, 100nM~
The range of 300nM include, but are not limited to this.RecG type unwindase can be relative to the RecG for above-mentioned Escherichia coli
Determining concentration range according to concentration range comparable in terms of unit of enzyme activity come using.
Reaction solution can also include ammonium salt.As the example of ammonium salt, ammonium sulfate, ammonium chloride and ammonium acetate can be enumerated.Especially
Preferred ammonium salt is ammonium sulfate.Ammonium salt in reaction solution can with the range of 0.1mM~100mM, preferably 0.1mM~50mM,
1mM~50mM, 1mM~20mM range include, but are not limited to this.
As one kind of second enzyme group, in the DNA ligase for using Escherichia coli as with DNA ligase activity
Enzyme when, include its co-factor, that is, NAD (nicotinamide adenine dinucleotide) in reaction solution.NAD can be in reaction solution
The range of 0.01mM~1.0mM, preferably 0.1mM~1.0mM, 0.1mM~0.5mM range include, but are not limited to this.
Reaction solution used in method of the invention can also include reducing agent.It, can as the example of preferred reducing agent
Enumerate DTT, beta -mercaptoethanol and glutathione.Preferred reducing agent is DTT.
Reaction solution used in method of the invention can be also comprising for making the regenerated enzyme of ATP and substrate.Again as ATP
The combination of the enzyme and substrate of raw system, can enumerate creatine kinase and creatine phosphate and pyruvate kinase and phosphoenolpyruvate third
Ketone acid.As the enzyme of ATP regenerating system, myokinase can be enumerated.The combination of the enzyme and substrate of preferred ATP regenerating system is creatine
Kinases and creatine phosphate.
Above-mentioned operation (2) is the process for reacting the reaction mixture formed in process (1).Process (2) can be
Such as the process within the temperature range of 15 DEG C~80 DEG C, 15~50 DEG C, 15 DEG C~40 DEG C reacting reaction mixture.It is excellent
Selection of land, process (2) can be the process kept the temperature under isothermal conditions.As isothermy, as long as DNA replication dna reaction can carry out
It is not particularly limited, can be set to contained certain temperature in the range of optimum temperature i.e. 20 DEG C~80 DEG C of such as archaeal dna polymerase
Degree, contained certain temperature in the range of can be set to 25 DEG C~50 DEG C are contained in the range of can be set to 25 DEG C~40 DEG C
Certain temperature can be set to 30 DEG C or so.In the present specification, " under isothermal conditions keep the temperature ", " being reacted under isothermal " art
Language refers to is held in above-mentioned temperature range in the reaction.Soaking time can be produced according to the duplication of the cyclic DNA as target
The amount of object or amplified production can be set to such as 1~24 hour being suitable for setting.
Alternatively, as above-mentioned operation (2), may include the reaction mixture that makes to be formed in process (1) by repeatedly into
The process being incubated under 30 DEG C of row or more of incubation and the temperature cycles of 27 DEG C of incubations below.As long as 30 DEG C or more of incubation
That the temperature range of the duplication that can originate the cyclic DNA comprising oriC is not particularly limited, can be such as 30~80 DEG C,
30~50 DEG C, 30~40 DEG C, 37 DEG C.30 DEG C or more of incubation is not particularly limited, and every 1 circulation can be 10 seconds~10 minutes.
As long as 27 DEG C of incubations below can inhibit replication initiation, the temperature for the extension for carrying out DNA is not particularly limited, such as
It can be 10~27 DEG C, 16~25 DEG C, 24 DEG C.27 DEG C of incubations below are not particularly limited, and preferably cooperate expanded ring-type
The length of DNA is to set, such as recycles for 1, and every 1000 base can be 1~10 second.The cycle-index of temperature cycles does not have
It is particularly limited to, can be 10~50 circulations, 20~40 circulations, 25~35 circulations, 30 circulations.
It, can be with after the process for keeping the temperature above-mentioned reaction mixture under isothermal conditions for the present processes
It include the process purified to duplication product or the amplified production of cyclic DNA according to purpose.The purifying of cyclic DNA can be used
The method that those skilled in the art can utilize is appropriately carried out.
It, can be straight by the reaction mixture after reaction about the cyclic DNA for using the present processes to replicate or amplify
Connect or suitable purification after for convert etc. subsequent purpose.
Clone method (A ') > of < cyclic DNA
It is known in the same manner as the combination of XerCD and dif, using Cre and its identify sequence loxP combination also may be implemented
The separation (Ip, S.C.Y., et al., EMBO J., 2003,22:6399-6407) of DNA polymer.The present inventors's discovery, makees
For the combined substitution of XerCD and dif in method (A), enzyme is separated using DNA polymer and its identifies that the combination of sequence can also
To inhibit the generation as the DNA polymer of by-product.
In a mode, this application involves a kind of duplication of the cyclic DNA in cell free system or amplification method (hereinafter,
It is denoted as " method (A ') " sometimes in the present specification), it includes processes below:
Process (1): being formed into the cyclic DNA of template and the reaction mixture of reaction solution, and the reaction solution includes following
Component:
First enzyme group of the duplication of catalysis cyclic DNA,
Catalysis Okazaki fragments connection reaction and be synthetically formed 2 sisters' cyclic DNAs of catenane second enzyme group and
It is catalyzed the third enzyme group of the separation reaction of 2 sisters' cyclic DNAs;With
Process (2): react the reaction mixture formed in process (1);
Here, the cyclic DNA include can with replication initiation sequence (the origin of in conjunction with the active enzyme of DnaA
Chromosome (oriC)) and also comprising being respectively relative to the 1 pair of ter sequence and/or DNA polymer that oriC is inserted into outward
The base sequence of enzyme identification is separated,
Here, in the case which has ter sequence, the reaction solution of foregoing sequence (1) also includes to have to be incorporated into
Ter sequence and inhibit duplication active protein, also, the cyclic DNA have DNA polymer separation enzyme identification base
In the case where sequence, the reaction solution of foregoing sequence (1) also includes DNA polymer separation enzyme.
That is, method (A') is " XerCD " in method (A) to be expanded to " DNA polymer separates enzyme ", by " XerCD is identified
Base sequence " expand to " and DNA polymer separate enzyme identification base sequence " range method.Accordingly, with respect to method (A)
It is each composition and be recorded in the explanation in the project of clone method (A) > of < cyclic DNA, method (A') is also suitable.
DNA polymer separation enzyme is the isolated enzyme that DNA polymer can be realized by generating genetic recombination.Identification is special
Fixed base sequence and can to can be used as DNA in the locus specificity recombinase that the base sequence position generates genetic recombination more
Aggressiveness separates enzyme and uses.The specific base sequence that DNA polymer separation enzyme is identified is denoted as " DNA polymer separation enzyme knowledge
Other base sequence ".By separating enzyme using DNA polymer and being separated the combination for the base sequence that enzyme identifies by DNA polymer
Genetic recombination, the separation of DNA polymer may be implemented.Method (A ') is able to suppress and using the mechanism as by-product
DNA polymer generation.Commercially available product can be used in DNA polymer separation enzyme, also can be used and extracts simultaneously from microorganism etc.
The enzyme generated as needed.Enzyme from microorganism extraction and purifying the method that those skilled in the art can utilize can be used
Suitably implement.
DNA polymer separation enzyme, which separate the combination of base sequence that enzyme identifies with the DNA polymer, to be enumerated: XerCD with
Dif sequence, Cre and loxP sequence (Siegel, R.W., et al.., FEBS Lett., 2001,499 (1-2): 147-153;
Araki, K., et al., Nucleic Acids Res.:1997,25 (4): 868-872), budding yeast (Saccharomyces
Verevisiae, Japanese: budding yeast) source recombinase FLP and FRT sequence (Broach, J.R., et al., Cell,
1982,29 (1): 227-234), recombinase DreO and rox sequence (Anastassiadis, K., the et in the source bacteriophage D6
Al., Dis.Model.Mech., 2009,2:508-515), the weight in the source Lu Shi yeast (zygosacchromyces rouxii)
Group enzyme R and RS sequence (Araki, H., et al., J.Mol.Biol., 1985,182 (2): 191-203), serine recombinase man
Race (such as Gin, γ δ, Tn3 and Hin) and their identification sequence (Smith, M.C., et al., Mol.Microbiol.,
2002,44:299), but these are not limited to.
About XerCD and dif sequence, as described in the project of clone method (A) > of < cyclic DNA.
About the combination of Cre and loxP sequence, biological origin is not particularly limited.Cre is preferably that bacteriophage P1 comes
The Cre albumen in source.Cre can include with the range of 0.01~200mU/ μ l in reaction solution, preferably can with 0.1~
150mU/ μ l, 0.1~100mU/ μ l, 0.5~100mU/ μ l, 0.5~80mU/ μ l, 0.1~50mU/ μ l, 1~50mU/ μ l, 1~
The range of 30mU/ μ l include, but are not limited to this.
The loxP sequence of Cre identification can be comprising the 5 '-ATAACTTCGTATAGCATACA as loxP consensus sequence
TTATACGAAGTTAT-3 ' (sequence number 30) or (lower-case portion is variation relative to consensus sequence as variation loxP sequence
Base) 5 '-ATAACTTCGTATAGtATACATTATACGAAGTTAT-3 ' (sequence number 31/lox511), 5 '-ATAACTTC
GTATAGgATACtTTATACGAAGTTAT-3 ' (sequence number 32/lox2272), 5 '-ATAACTTCGTATAtacctttcTATA
CGAAGTTAT-3 ' (sequence number 33/loxFAS), 5 '-ATAACTTCGTATAGCATACATTATACGAAcggta-3 ' (sequence number
34/lox RE), 5 '-taccgTTCGTATAGCATACATTATACGAAGTTAT-3 ' (sequence number 35/lox LE) or they in
The complementary series of any one sequence.
The recombinase FLP in the source budding yeast (Saccharomyces verevisiae) can be with 1nM in reaction solution
The range of~200nM includes, preferably can with 5nM~200nM, 5nM~150nM, 10nM~200nM, 10nM~150nM,
20nM~200nM, 20nM~150nM, 20nM~100nM range include, but are not limited to this.The FRT sequence that FLP is identified
It can be the sequence comprising 5 '-GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC-3 ' (sequence number 36) or its complementary series
Column.
The recombinase DreO in the source bacteriophage D6 can be with the range of 1nM~200nM including preferably may be used in reaction solution
With with 5nM~200nM, 5nM~150nM, 10nM~200nM, 10nM~150nM, 20nM~200nM, 20nM~150nM,
The range of 20nM~100nM include, but are not limited to this.The rox sequence that DreO is identified can be comprising 5 '-TAACTTTAA
The sequence of ATAATGCCAATTATTTAAAGTTA-3 ' (sequence number 37) or its complementary series.
The recombinase R in the source Lu Shi yeast (zygosacchromyces rouxii) in reaction solution can with 1nM~
The range of 200nM includes, preferably can with 5nM~200nM, 5nM~150nM, 10nM~200nM, 10nM~150nM,
20nM~200nM, 20nM~150nM, 20nM~100nM range include, but are not limited to this.The RS sequence that enzyme R is identified
Can be includes Araki, sequence or its complementary series disclosed in H. etc. (J.Mol.Biol., 1985,182 (2): 191-203)
Sequence.
Serine recombinates enzyme family (γ δ, Tn3, Gin and Hin) can be come in reaction solution with the range of 1nM~200nM
Include, it preferably can be with 5nM~200nM, 5nM~150nM, 10nM~200nM, 10nM~150nM, 20nM~200nM, 20nM
~150nM, 20nM~100nM range include, but are not limited to this.γ δ, Tn3 and their identification sequence res can be packet
Sequence disclosed in (Cell, 1982,30:19-27) such as N.D.F.. containing Grindley or the sequence of its complementary series.Gin and
It identifies that sequence can be comprising sequence disclosed in Kahmann.R. etc. (Cell, 1985,41:771-780) or its complementary sequence
The sequence of column.Hin and its identification sequence can be comprising (J.Biol.Chem., 1989,264:10072- such as Glasgow.A.C.
10082) sequence of sequence or its complementary series disclosed in.
The sequence of DNA polymer separation enzyme identification can reside in any position on cyclic DNA.For example, DNA polymer
The sequence of separation enzyme identification can reside in region near oriC or adjacent, and can also exist on becomes phase relative to oriC
The region of opposite side.
Clone method (B) > of < cyclic DNA
In a mode, this application involves a kind of duplication of the cyclic DNA in cell free system or amplification method (hereinafter,
It is denoted as " method (B) " sometimes in the present specification), it includes processes below:
Process (1): oriC transposons and transposase being added in buffer and form oriC swivel base body, here, oriC
Transposons be comprising can with replication initiation sequence (the origin of chromosome in conjunction with the active enzyme of DnaA
(oriC)) linear DNA and the linear DNA for its two end comprising outer end (OE) sequence;
It reacts oriC swivel base body and the cyclic DNA without oriC in buffer, carries out transfer reaction;
Thus the process of the cyclic DNA comprising oriC is prepared;
Process (2): the reaction mixture of cyclic DNA and reaction solution obtained in formation process (1) comprising oriC, it is described
Reaction solution includes following components:
First enzyme group of the duplication of catalysis cyclic DNA,
Catalysis Okazaki fragments connection reaction and be synthetically formed 2 sisters' cyclic DNAs of catenane second enzyme group and
It is catalyzed the third enzyme group of the separation reaction of 2 sisters' cyclic DNAs;With
Process (3): react the reaction mixture formed in process (2).
Although being not limited by theory, method (B) using transposons into the cyclic DNA without oriC by being imported
OriC, to prepare the cyclic DNA comprising oriC, duplication or expand cyclic DNA that this includes oriC.By schematic diagram in Fig. 2.
In Fig. 2, the process represented by " transposons is formed ", " transfer reaction " corresponds to above-mentioned operation (1).With regard to replicating or expand and
Speech by replication cycle shown in FIG. 1 or is repeated the replication cycle and replicates or expand in above-mentioned operation (2) and (3)
Cyclic DNA.The definition of duplication and amplification about cyclic DNA, as described in method (A).
About the cyclic DNA comprising oriC mixed with reaction solution, according to the note in the project of above-mentioned < cyclic DNA >
It carries.The amount of cyclic DNA comprising oriC used in every 1 reaction is as described in the amount the template DNA in method (A).
In addition, the explanation for the other ingredients that may include in enzyme group, reaction solution contained in reaction solution, with method (A)
In it is identical.Further, the process (2) in above-mentioned operation (3) and method (A) equally carries out.About also comprising to cyclic DNA
The process this point that duplication product or amplified production are purified and the ring-type for replicating or amplifying using the present processes
The application of DNA, it is also identical with method (A).
As long as known to those skilled in the art its of the OE sequence at the both ends of oriC transposons is identified by transposase, be can be used as
The sequence that OE sequence uses then can be arbitrary sequence.In preferred embodiment, OE sequence includes sequence number 25 (5 '-
CTGTCTCTTATACACATCT-3 ') shown in sequence or its complementary series, process (1) linear DNA 5 ' ends be inserted into
Have the OE sequence comprising sequence shown in sequence number 25, in 3 ' ends of the linear DNA inserted with comprising shown in sequence number 25
The OE sequence of the complementary series of sequence.
In above-mentioned operation (1), oriC swivel base body formed used in oriC transposons concentration can be 20~
200nM can be preferably 40~160nM.
As long as transposase identification OE sequence and formed swivel base body, cyclic DNA transfer transfer stand DNA enzyme, then its
Biological origin is not particularly limited, and can be suitable for the transposase using such as Escherichia coli.Particularly preferably high work
Property Tn5 variation (E54K, L372P) albumen (Goryshin, I.Y., and Reznikoff, W.S., J.Biol.Chem., 1998,
273:7367-7374).Commercially available product can be used in transposase, also can be used and extracts from microorganism etc. and purify as needed
Transposase afterwards.Enzyme from microorganism extraction and purifying method that those skilled in the art can utilize can be used suitably
Implement.In the case where using high activity Tn5 variation (E54K, L372P) albumen as transposase, in above-mentioned operation (1),
Concentration used in the formation of oriC swivel base body can be 50~200nM, can be preferably 80~150nM.
Process (1) as long as used in buffer it is slow in pH6~9, be preferably suitable for for use under pH7.5
Fliud flushing is then not particularly limited.It can be mentioned, for example Tris- acetic acid, Tris-HCl, Hepes-KOH, phosphate buffer, MOPS-
NaOH, Tricine-HCl etc..Preferred buffer is Tris- acetic acid or Tris-HCl.The concentration of buffer can be by this field
Technical staff suitably selects, and is not particularly limited, and in the case where Tris- acetic acid or Tris-HCl, can choose such as 10mM
~100mM, 10mM~50mM, 20mM concentration.
In process (1), formed oriC swivel base body process by 30 DEG C or so at a temperature of keep the temperature 30 minutes or so
Come carry out.
The transfer reaction of process (1) is in the optimum temperature of transposase, carry out at such as 37 DEG C.Carry out the time of transfer reaction
It can suitably be selected, such as can be 15 minutes or so by those skilled in the art.In addition, in the transfer reaction of process (1),
TRNA can be added.In the transfer reaction of process (1), the concentration for adding tRNA can choose such as 10~200ng/ μ l, 30
The concentration of~100ng/ μ l, 50ng/ μ l.
In a mode, the cyclic DNA comprising oriC of process (2) can be also inserted into comprising being respectively relative to oriC outward
1 pair of ter sequence and/or the base sequence that is identified by DNA polymer separation enzyme such as XerCD, Cre.In this case, in the ring
In the case that shape DNA has ter sequence, the reaction solution of foregoing sequence (2) also includes to have to be incorporated into ter sequence and inhibit to replicate
Active protein, also, the base sequence that in the cyclic DNA there is XerCD, Cre etc. to be identified by DNA polymer separation enzyme
In the case where, the reaction solution of foregoing sequence (2) also includes the DNA polymer such as XerCD, Cre separation enzyme.
Alternatively, in another way, according to make to be respectively relative to 1 pair of ter sequence that oriC is inserted into outward and/or XerCD,
Cre etc. is prepared by the mode that the base sequence that DNA polymer separation enzyme identifies is contained in a part of oriC transposons,
For the base sequence that 1 pair of ter sequence and/or XerCD, Cre etc. are identified by DNA polymer separation enzyme, swivel base also can use
Son is imported into cyclic DNA.That is, the linear DNA of process (1) also includes to be respectively relative to oriC to be inserted into outward in which
1 pair of ter sequence and/or the base sequence that is identified by DNA polymer separation enzyme such as XerCD, Cre, and have in the linear DNA
In the case where having ter sequence, the reaction solution of foregoing sequence (2) also includes with the activity for being incorporated into ter sequence and inhibiting to replicate
Protein, and the cyclic DNA have XerCD, Cre etc. by DNA polymer separation enzyme identify base sequence the case where
Under, the reaction solution of foregoing sequence (2) also includes XerCD albumen.
Here, about 1 pair of ter sequence and/or XerCD, Cre that oriC is inserted into outward etc. is respectively relative to by DNA poly
Body separation enzyme identification base sequence and be incorporated into ter sequence and inhibit duplication active protein and/or
The DNA polymer such as XerCD, Cre separates the definition and explanation of enzyme, to as described in method (A) or method (A').
In a mode, method (B) can also include process (4): replicating or expand from the reaction product in process (3)
Cyclic DNA in remove oriC transposons.
Remove oriC transposons process may include: using 0.1~30nM, preferably 1~20nM, more preferably 3~
The processing of the transposase of 10nM;With utilize the straight-chain double-stranded DNA dependence single stranded DNA exonuclease of ExoIII etc
The single stranded of the end DNA is handled.Buffer used in processing using transposase can be used to be delayed used in process (1)
Fliud flushing.The buffer used in the processing using single stranded DNA exonuclease, as long as single stranded DNA exonuclease rises
The buffer of any composition then can be used in the condition of effect.
In addition, the process for removing oriC transposons can be also comprising using contained in the sequence for corresponding to oriC transposons
The processing of the restriction enzyme of restriction enzyme sites.The purpose of the processing is specificity cutting oriC transposons.Therefore, it selects at this time
Include in oriC transposons but is free of in the region other than the oriC swivel base subregion in the cyclic DNA that duplication amplifies
Restriction enzyme position corresponding to restriction enzyme.It, can in order to carry out the specific double-strand cutting in region contained in oriC transposons
To use CRISPR-Cas9 to replace restriction enzyme.In this case, the specific sequence in region contained in oriC transposons is specified
As guide RNA.
< functionality box (nucleic acid) >
In a mode, this application involves comprising oriC and be respectively relative to 1 pair of ter sequence that oriC is inserted into outward
And/or XerCD, Cre etc. are by the nucleic acid of the base sequence of DNA polymer separation enzyme identification.Preferably, aforementioned nucleic acid is threadiness
DNA, it is further preferred that aforementioned nucleic acid is double-strandednucleic acid.The length of aforementioned nucleic acid does not have as long as the preparation that can be used for cyclic DNA
It is particularly limited to.In preferred embodiment, the length of aforementioned nucleic acid be 273bp~2.0kb, 273bp~1.5kb or 273bp~
The length of 1.0kb.The shortest length of aforementioned nucleic acid is 273bp, oriC 245bp, and in 1 pair of ter sequence or DNA polymer
Separating shortest dif sequence in enzyme recognition sequence is 28bp, is thus length when being directly connected to these.
Above-mentioned nucleic acid can be used as the function being used to prepare in the present processes (A) as the cyclic DNA of template
Property box come using.
In another way, this application involves comprising oriC and be respectively relative to 1 pair of ter sequence that oriC is inserted into outward
And/or XerCD, Cre etc. by the base sequence of DNA polymer separation enzyme identification and include outer end (OE) sequence in two ends
Nucleic acid.Preferably, aforementioned nucleic acid is linear DNA, it is further preferred that aforementioned nucleic acid is double-strandednucleic acid.The length of aforementioned nucleic acid
As long as the preparation that degree can be used for cyclic DNA is not particularly limited.In preferred embodiment, the length of aforementioned nucleic acid is 311bp
The length of~2.0kb, 311bp~1.5kb or 311bp~1.0kb.The shortest length of aforementioned nucleic acid is 311bp, and oriC is
245bp, shortest dif sequence is 28bp, also, 2 OE sequences in 1 pair of ter sequence or DNA polymer separation enzyme recognition sequence
It is classified as 38bp, is thus length when being directly connected to these.
Above-mentioned nucleic acid can come in the present processes (B) as the functional box for playing the role of oriC transposons
It utilizes.
Here, about 1 pair of ter sequence and/or XerCD, Cre that oriC is inserted into outward etc. is respectively relative to by DNA poly
Body separation enzyme identification base sequence and be incorporated into ter sequence and inhibit duplication active protein and/or
The DNA polymer such as XerCD, Cre separates the definition and explanation of enzyme, to as described in method (A) and method (A').
Above-mentioned functional box is reducing the cyclic DNA comprising oriC for the template for becoming method (A), (A ') and (B)
It is useful in terms of preparation cost.
< kit >
In a mode, this application involves a kind of duplications of cyclic DNA or reagent for amplification box (hereinafter, in this specification
In, it is denoted as " kit (A) " sometimes), it includes the combinations of following components:
It is catalyzed the first enzyme group of the duplication of cyclic DNA;
The second enzyme group of 2 sisters' cyclic DNAs of catenane is reacted and is synthetically formed in catalysis Okazaki fragments connection;
It is catalyzed the third enzyme group of the separation reaction of 2 sisters' cyclic DNAs;
Comprising oriC and 1 pair of ter sequence and/or XerCD, Cre that oriC is inserted into outward are respectively relative to etc. by DNA
Polymer separates the linear DNA of the base sequence of enzyme identification;And
There is the active albumen for being incorporated into ter sequence and inhibiting duplication in the case where the linear DNA is with ter sequence
Matter, and/or in the case where the base sequence that there is the linear DNA XerCD, Cre etc. to be identified by DNA polymer separation enzyme it is right
Enzyme should be separated in the DNA polymer such as XerCD, Cre of the sequence.Kit (A) be for carry out the present processes (A) or
The kit of (A ').
The specific ingredient and concentration that product are respectively constituted contained in kit (A) of the invention, according to above-mentioned <
One, in the project of amplification method (A ') > of amplification method (A) >, < cyclic DNA of second, third enzyme group >, < cyclic DNA
Record.
In another way, this application involves the duplications of cyclic DNA or the combination of reagent for amplification box (hereinafter, in this theory
In bright book, " kit (B) " is denoted as sometimes), it includes the combinations of following components:
It is catalyzed the first enzyme group of the duplication of cyclic DNA;
The second enzyme group of 2 sisters' cyclic DNAs of catenane is reacted and is synthetically formed in catalysis Okazaki fragments connection;
It is catalyzed the third enzyme group of the separation reaction of 2 sisters' cyclic DNAs;
OriC transposons, here, oriC transposons be comprising can with the replication initiation in conjunction with the active enzyme of DnaA
The linear DNA of sequence (origin of chromosome (oriC)) and for its two end include outer end (OE) sequence threadiness
DNA;With
Transposase.Kit (B) is the kit for carrying out the present processes (B).
In certain mode, the oriC transposons in kit (B) can be also comprising being respectively relative to oriC is inserted into outward 1
The base sequence that ter sequence and/or XerCD, Cre etc. are identified by DNA polymer separation enzyme.In this case, kit
It (B) can be also comprising inhibiting in the active protein and/or insertion oriC transposons of duplication with ter sequence is incorporated into
DNA polymer separation enzyme corresponding to the sequence identified by DNA polymer separation enzyme.
The specific ingredient and concentration of product are respectively constituted contained in kit (B) of the invention, such as above-mentioned < first,
Record in the project of amplification method (B) > of second, third enzyme group >, < cyclic DNA.
For the kit (A) of the application and (B), above-mentioned composition product can all be covered in 1 kit, separately
Outside, it is the kit used in the present processes if it is purpose, a part of above-mentioned composition product can also not be included.
When for the kit of a part not comprising above-mentioned composition product, implementer can be additional necessary into the kit in amplification
Ingredient and the amplification method (A) and (B) for implementing the application respectively.
The kit (A) of the application and (B) can be also comprising additional composition product, and the addition composition product include to be selected from albumen
The non-specific adsorption inhibitor of matter, the non-specific adsorption inhibitor of nucleic acid, straight-chain DNA specificity exonuclease,
One or more of the combination of enzyme and substrate of RecG type unwindase, ammonium salt, NAD, reducing agent and ATP regenerating system at
Point.Additional composition product can be used as 1 kit and be included in the kit of the application, alternatively, can also be used as with this
Separate agent box premised on the kit of application is used together provides.
For the kit (A) of the application and (B), may include the mixtures of above-mentioned composition product is packed into 1 and
At package body, also may include by single above-mentioned composition product or several above-mentioned composition product mix after independently pack
Package body.The kit (A) of the application and (B) in addition can separately include the cyclic DNA recorded for implementing the application
Amplification method (A) and (B) instruction specification.
Embodiment
Hereinafter, illustrating the present invention based on embodiment.It should be noted that the present invention is not recorded by following embodiments
Range limit.
Embodiment 1: the duplication for the cyclic DNA of termination sequence ter and Tus albumen inhibited with DNA polymer is utilized
< material and method >
It is prepared into the cyclic DNA of template as follows.It is inserted into oriC segment into M13mp18 plasmid vector, 8.0kb ring is made
Shape DNA.The region insertion of the opposite side as oriC in the 8.0kb cyclic DNA includes 2 opposite (lower stroke of ter sequence
Line) DNA fragmentation ((5 '-ACTTTAGTTACAACATACTTATT-N176-AATAAGTATGTTGTAACTAAAGT-3 ' (sequence
Number 26)), the 8.0kb cyclic DNA ((a) of Fig. 3) for inserting ter is made.Use the 8.0kb cyclic DNA of insertion ter as mould
Plate DNA uses 8.0kb cyclic DNA as the comparison DNA for being free of ter sequence.
Tus is raw by the inclusion of the process of affinity column chromatography and gel filtration column chromatography by the Bacillus coli expression strain of Tus
At, preparation.
Prepare the reaction solution of composition shown in table 1 and other than forming shown in table 1 also with final concentration 2nM or 5nM
Mode is added with the reaction solution of Tus.Added in a manner of final concentration of 0.8ng/ μ l respectively into these reaction solutions template DNA or
Comparison DNA keeps the temperature 1 hour in 30 DEG C of incubator, to be reacted after mixing on ice.It is every 1 reaction total volume be
10 microlitres.[α-is first added into reaction solution32P] dATP, after DNA replication dna reaction, to a part progress agarose of reaction solution
After gel electrophoresis (0.5%1 × TAE, 150V, 100 minutes, 14 DEG C), is detected and taken in BAS imaging plate32The product of P, confirmation produce
Target supercoil product structure is given birth to.
[table 1]
In table, SSB indicates that Escherichia coli SSB, IHF indicate the complex of Escherichia coli IhfA and IhfB,
DnaG indicates that Escherichia coli DnaG, DnaN indicate that Escherichia coli DnaN, PolIII* are indicated by Escherichia coli
The DNA polymerase i II* as complex that DnaX, HolA, HolB, HolC, HolD, DnaE, DnaQ and HolE are constituted is compound
Body, DnaB indicate that Escherichia coli DnaB, DnaC indicate that Escherichia coli DnaC, DnaA indicate Escherichia coli
RNaseH, Ligase indicate that Escherichia coli DNA ligase, PolI indicate Escherichia coli DNA polymerase i, GyrA table
Show that Escherichia coli GyrA, GyrB indicate that Escherichia coli GyrB, Topo IV indicate Escherichia coli ParC and ParE
Complex, Topo III indicate Escherichia coli topoisomerase II I, RecQ indicate Escherichia coli RecQ.
SSB is the process from the Bacillus coli expression strain of SSB by the inclusion of ammonium sulfate precipitation and ion exchange column chromatography
Purifying, preparation.
IHF is from the coexpression strain of the Escherichia coli of IhfA and IhfB by the inclusion of ammonium sulfate precipitation and affinity column chromatography
Process purifying, preparation.
DnaG be from the Bacillus coli expression strain of DnaG by the inclusion of ammonium sulfate precipitation, Anion exchange column chromatography and
Gel filtration column chromatography process purifying, preparation.
DnaN is from the Bacillus coli expression strain of DnaN by the inclusion of ammonium sulfate precipitation and Anion exchange column chromatography
Process purifying, preparation.
PolIII* is to co-express strain from the Escherichia coli of DnaX, HolA, HolB, HolC, HolD, DnaE, DnaQ and HolE
In by the inclusion of ammonium sulfate precipitation, affinity column chromatography and gel filtration column chromatography process purifying, preparation.
DnaB, DnaC are from the coexpression strain of the Escherichia coli of DnaB and DnaC by the inclusion of ammonium sulfate precipitation, affinity column
The process of chromatography and gel filtration column chromatography purifying, preparation.
DnaA is from the Bacillus coli expression strain of DnaA by the inclusion of ammonium sulfate precipitation, dialysis precipitating and gel filtration
Column chromatography process purifying, preparation.
GyrA, GyrB are passed through from the mixture of the Bacillus coli expression strain of the Bacillus coli expression strain and GyrB of GyrA
Process purifying, preparation comprising ammonium sulfate precipitation, affinity column chromatography and gel filtration column chromatography.
Topo IV is to pass through packet from the mixture of the Bacillus coli expression strain of the Bacillus coli expression strain and ParE of ParC
Liquid containing ammonium sulfate precipitating, the process of affinity column chromatography and gel filtration column chromatography purifying, preparation.
Topo III is from the Bacillus coli expression strain of Topo III by the inclusion of ammonium sulfate precipitation and affinity column chromatography
Process purifying, preparation.
RecQ is from the Bacillus coli expression strain of RecQ by the inclusion of ammonium sulfate precipitation, affinity column chromatography and gel mistake
Filter column chromatography process purifying, preparation.
RNaseH, Ligase, PolI have used the enzyme (Takara Shuzo Co., Ltd.) of commercially available Escherichia coli.
< result >
The testing result for replicating product is shown in Fig. 3.
It has been confirmed that using the case where 8.0kb cyclic DNA of insertion ter is as including Tus in template and reaction solution
Under, inhibit the generation of the polymer as by-product and replicates or expand the cyclic DNA of target supercoil product structure.It is another
Aspect, the case where Tus is free of in the case where using the 8.0kb cyclic DNA without ter sequence as template and in reaction solution
Under, although observing the generation of the cyclic DNA of target supercoil product structure, also observe the polymer as by-product
Generation.
Tus-ter system is that the mechanism of duplication termination is carried out in circular chromosome.Experimental result shown in the present embodiment is true
Recognize: by the duplication amplified reaction of cyclic DNA group enter the system, be able to suppress the generation of non-specific DNA polymer.
Embodiment 2: the cyclic DNA of locus specificity recombination sequence dif and XerCD inhibited with DNA polymer is utilized
Duplication
< material and method >
In the way of including dif sequence (sequence number 22) in the region in the opposite side as oriC of cyclic DNA, lead to
Recombining reaction in Bacillus coli cells is crossed to be prepared into the 12kb cyclic DNA ((a) of Fig. 4) inserted with dif of template.Specifically
For, it using the Escherichia coli of the recombinant protein group of expression λ bacteriophage, is reacted by in-vivo recombination, preparation contains
The upstream side the dif region 4.2kb of the box and escherichia coli chromosome of oriC and kalamycin resistance gene and downstream side
The cyclic DNA of the target length in the region 6.0kb.
As the comparison DNA for being free of dif sequence, the 8.0kb cyclic DNA recorded in embodiment 1 is used.
XerCD is from the coexpression strain of the Escherichia coli of XerC and XerD by the inclusion of ammonium sulfate precipitation, affinity column chromatography
Process purifying, preparation.
Prepare the reaction solution of composition shown in the table 1 of embodiment 1 and other than forming shown in table 1 also with final concentration
The mode of 3.5nM, 7nM, 14nM or 35nM are added with the reaction solution of XerCD.Into these reaction solutions respectively with final concentration
The mode of 0.8ng/ μ l adds template DNA or comparison DNA, after mixing on ice, keeps the temperature 1 hour in 30 DEG C of incubator, from
And it is reacted.The total volume of every 1 reaction is 10 microlitres.[α-is first added into reaction solution32P] dATP, similarly to Example 1
It detects the by-product after reacting, confirm its structure.
< result >
The testing result for replicating product is shown in (b) of Fig. 4.
It has been confirmed that use the 12kb cyclic DNA inserted with dif as in template and reaction solution include XerCD feelings
Under condition, inhibits the generation of the polymer as by-product and replicate or amplify the cyclic DNA of target supercoil product structure.Separately
On the one hand, be free of XerCD's in the case where using the 8.0kb cyclic DNA without dif sequence as template and in reaction solution
In the case of, it observes the generation of the cyclic DNA of target supercoil product structure, but also observes the polymer as by-product
Generation.
XerCD-dif system is that the mechanism of chromosome separation is carried out in circular chromosome.That is, XerCD-dif system is
Carry out the isolated mechanism of DNA polymer.The confirmation of experimental result shown in the present embodiment: pass through the duplication expansion in cyclic DNA
Increase group in reaction and enter the system, is able to suppress the generation of non-specific DNA polymer.
Embodiment 3: it is influenced caused by the position of ter sequence or dif sequence in cyclic DNAIn Examples 1 and 2,
Template DNA is prepared in the way of the region for the opposite side as oriC that ter sequence or dif sequence are located in cyclic DNA.
In embodiment 3, near oriC or the cyclic DNA of adjacent position, carrying out ter sequence or the configuration of dif sequence
Duplication amplified reaction.
< material and method >
In order to construct 15kb cyclic DNA, the 15kbDNA of oriC is free of using genome of E.coli as template amplification, preparation
Segment.
It is following to prepare 15kb-ori-ter ring-type as cyclic DNA of the position configured with ter sequence near oriC
DNA.Ori-ter box, cyclisation, to make (Fig. 5) are connected in above-mentioned 15kbDNA segment.Ori-ter box (0.38kb)
Sequence is as follows, has outside ter sequence (underscore) at the both ends of oriC box (lowercase).
Ori-ter box: 5 '-AGTATGTTGTAACTAAAGATAACTTCGTATAATGTATGCTATACGAAGTTATaca
gatcgtgcgatctactgtggataactctgtcaggaagcttggatcaaccggtagttatccaaagaacaactgttgt
tcagtttttgagttgtgtataacccctcattctgatcccagcttatacggtccaggatcaccgatcattcacagtt
aatgatcctttccaggttgttgatcttaaaagccggatccttgttatccacagggcagtgcgatcctaataagaga
tcacaatagaacagatctctaaataaatagatcttctttttaatacccaggatccATTTAACATAATATACATTAT
GCGCACCTTTAGTTACAACATACT- 3 ' (sequence numbers 27)
It is following to prepare 15kb-ori-dif ring-type as cyclic DNA of the position configured with dif sequence near oriC
DNA.Ori-dif box, cyclisation, to make (Fig. 5) are connected in above-mentioned 15kbDNA segment.Ori-dif box (0.32kb)
Sequence is as follows, it is adjacent in the upstream side of oriC box (lowercase) and have dif sequence (underscore).
Ori-dif box: 5 '-ATTTAACATAATATACATTATGCGCACCAAGTATacagatcgtgcgatctactgt
ggataactctgtcaggaagcttggatcaaccggtagttatccaaagaacaactgttgttcagtttttgagttgtgt
ataacccctcattctgatcccagcttatacggtccaggatcaccgatcattcacagttaatgatcctttccaggtt
gttgatcttaaaagccggatccttgttatccacagggcagtgcgatcctaataagagatcacaatagaacagatct
Ctaaataaatagatcttctttttaatacccaggatcc-3 ' (sequence number 28)
The DNA polymer of ter and Tus is depended on to generate inhibition in order to study, in addition to composition shown in table 2 below
In reaction solution also in a manner of final concentration of 0,2,6,20 or 60nM added with Tus, with final concentration of 0.5ng/ μ l, 5pg/ μ
L, cyclic DNA is added in the mode of 50fg/ μ l or 0.5fg/ μ l, reacts 3 hours or 17 hours at 30 DEG C.
Inhibit to study DNA polymer caused by XerCD and generate, also in addition to composition shown in table 2 below
In reaction solution in a manner of 0,30 or 60nM of final concentration added with XerCD, ring-type is added in a manner of final concentration 0.5ng/ μ l
DNA reacts 2 hours at 30 DEG C.
For reaction product, carry out agarose gel electrophoresis (0.5%1 × TBE, 60V, 60 minutes), with SybrGreen I
(Takara Shuzo Co., Ltd.) dyeing, detects DNA.
[table 2]
Each enzyme in table is enzyme identical with the enzyme recorded in embodiment 1, by preparing with the method recorded in embodiment 1
Or it obtains.
1 > of < result is generated dependent on the DNA polymer of ter and Tus to be inhibited
(1) Tus is titrated
The testing result for replicating amplified production is shown in Fig. 6.Template DNA amount is 0.5ng/ μ l, uses amount shown in fig. 6
Tus, carried out at 30 DEG C 3 hours react.
It may validate that in the case where using 15kb-ori-ter cyclic DNA as including Tus in template and reaction solution,
Inhibit the generation of the polymer as by-product and replicates or amplify the cyclic DNA of target supercoil product structure.In addition, logical
The Tus concentration improved in reaction solution is crossed, the effect of the generation of polymer is inhibited to get a promotion.Specifically, with 20nM or
For 60nM there are in the case where Tus, the generation of polymer is reduced to the level that can hardly confirm.
On the other hand, may validate that use 15kb-ori-dif cyclic DNA as in template and reaction solution comprising Tus
In the case of, the effect for inhibiting polymer to generate is not observed.This shows that Tus-ter system generates inhibitory effect to polymer and has
Contribution.
In addition, the above results show that ter sequence is configured near oriC or phase in the cyclic DNA for becoming template
In the case where adjacent position, also obtains DNA polymer and generate inhibitory effect.That is, insertion position of the ter sequence in cyclic DNA
Inhibitory effect will not be generated to DNA polymer to impact.
(2) DNA is titrated
The testing result for replicating amplified production is shown in Fig. 7.Using the template DNA and Tus of amount shown in Fig. 7,30
It carries out reacting for 17 hours at DEG C.
It may validate that in the case where using 15kb-ori-ter cyclic DNA as including Tus in template and reaction solution,
Inhibit the generation of the polymer as by-product and replicates or amplify the cyclic DNA of target supercoil product structure.In particular,
Even if template DNA amount is reduced to 0.5fg/ μ l, the effect can also be observed that.
DNA polymer caused by 2 > XerCD of < result, which generates, to be inhibited
The testing result for replicating amplified production is shown in Fig. 8.Template DNA amount is 0.5ng/ μ l, uses amount shown in Fig. 8
XerCD, carried out at 30 DEG C 2 hours react.
It may validate that when using 15kb-ori-dif cyclic DNA as including XerCD in template and reaction solution, inhibit
The generation and duplication of polymer as by-product or the cyclic DNA for amplifying target supercoil product structure.In addition, by by
The XerCD concentration in reaction solution is gradually improved, the effect for inhibiting polymer to generate also is promoted.
In addition, the above results show: dif sequence is being configured near oriC or phase in the cyclic DNA for becoming template
When the position of neighbour, also obtains DNA polymer and generate inhibitory effect.That is, insertion position of the dif sequence in cyclic DNA will not be right
DNA polymer generates inhibitory effect and impacts.
According to the above results 1 and 2, even if ter sequence and dif sequence are configured adjacently or configure with oriC in its vicinity,
It efficiently works, DNA polymer is inhibited to generate.Ter sequence and dif sequence can be only fitted to this point near oriC, meaning
Taste functional box can be made together with oriC in these sequences and be used for the building of cyclic DNA.
Embodiment 4: (1) is imported using the oriC box of transposons
In order to carry out the duplication or amplification of cyclic DNA using the present processes, need into the cyclic DNA for becoming template
Import oriC.In example 4, research and utilization transposons imports oriC box (Fig. 2).
< material and method >
As transposase (Tnp), high activity Tn5 variation (E54K, L372P) protein is used.The protein is from large intestine
Bacillus express strain in by the inclusion of ammonium sulfate precipitation, affinity column chromatography process purifying, preparation.
As oriC transposons, will there are the following of outer end (OE) sequence (underscore) at the both ends of the sequence comprising oriC
It is used after the 5 ' phosphorylation of DNA fragmentation of Sequence composition.
OriC transposons: 5 '-CTGTCTCTTATACACATCTgaagatccggcagaagaatggctgggatcgtgggt
taatttactcaaataagtatacagatcgtgcgatctactgtggataactctgtcaggaagcttggatcaaccggta
gttatccaaagaacaactgttgttcagtttttgagttgtgtataacccctcattctgatcccagcttatacggtcc
aggatcaccgatcattcacagttaatgatcctttccaggttgttgatcttaaaagccggatccttgttatccacag
ggcagtgcgatcctaataagagatcacaatagaacagatctctaaataaatagatcttctttttaatacccaggat
cccaggtctttctcaagccgacAGATGTGTATAAGAGACAG- 3 ' (sequence numbers 29)
About oriC transfer reaction, by 116nM Tnp and 48nM oriC transposons in buffer (10mM Tris- acetic acid
[pH 7.5], 15%glycerol, 50mM potassium glutamate, 1mM DTT, 0.1mM EDTA) at 30 DEG C keep the temperature 30 minutes and
Form oriC swivel base body.By oriC swivel base body (0.5 μ l) and target DNA (10fM) in buffer (5 μ l;10mM Tris-HCl[pH
7.5], 150mM potassium glutamate, 10mM Mg (oAc)2) in keep the temperature 15 minutes at 37 DEG C, carry out transfer reaction.As target DNA,
Use the bacillus coli gene expression plasmid from 15kb or the thermus thermophilus (Thermus as height Thermophilic Bacteria
Thermophilus the 9.3kb plasmid (pTT8 plasmid)) extracted in HB8 plants.Then it carries out at 70 DEG C at 5 minutes heat inactivations
Reason.
In the reaction solution of composition shown in table 2 to embodiment 3, the reaction mixture of above-mentioned oriC transfer reaction is added
A part (0.5 μ l), reacted 3 hours at 30 DEG C.For reaction product, carry out agarose gel electrophoresis (0.5%1 ×
TBE, 60V, 60 minutes), it is dyed with SybrGreen (Takara Shuzo Co., Ltd.), detects DNA.
< result >
The bacillus coli gene expression plasmid for using 15kb is shown in Fig. 9 as result when target DNA, will use from as
Result when the 9.3kb plasmid (pTT8 plasmid) extracted in HB8 plants of thermus thermophilus of height Thermophilic Bacteria is as target DNA is shown in figure
10。
A part that the reaction mixture of the oriC transfer reaction of Tnp will be present is used for the duplication amplification side of cyclic DNA
When method, the generation as duplication product/amplified production supercoil product is confirmed.On the other hand, in oriC transfer reaction not
There are in the case where Tnp, duplication product/amplified production is not confirmed carrying out the duplication amplification method of cyclic DNA yet.
In addition, the above results show: particularly, can also for 10fM (0.1pg/ μ l) this very low concentration of target DNA
Efficiently to import oriC, and can be expanded by the duplication amplification method of the cyclic DNA of the application.This shows: passing through
OriC box is set to carry out transposons, the readily and efficiently rate that realizes imports oriC into target DNA, and thus obtained includes
The cyclic DNA of oriC is efficiently amplified also by the duplication amplification method of the cyclic DNA of the application.
Embodiment 5: (2) are imported using the oriC box of transposons
Transposase (Tnp) and oriC transposons use enzyme and transposons same as Example 4.
About oriC transfer reaction, by 116nM Tnp and 144nM oriC transposons in buffer (10mM Tris- acetic acid
[pH 7.5], 15%glycerol, 50mM potassium glutamate, 1mM DTT, 0.1mM EDTA) at 30 DEG C keep the temperature 30 minutes and
Form oriC swivel base body.By oriC swivel base body (0.5 μ l), target DNA (1pM (50pg (3 × 106Molecule)/5 μ l) and tRNA
(50ng/ μ l) is in buffer (5 μ l;10mM Tris-HCl [pH 7.5], 150mM potassium glutamate, 10mM Mg (oAc)2) in
15 minutes are kept the temperature at 37 DEG C, carries out transfer reaction.As target DNA, the bacillus coli gene expression plasmid of 15kb is used.Then into
70 DEG C of row, the processing of 5 minutes heat inactivations.
The reaction mixing of above-mentioned oriC transfer reaction is added in the 5 μ l of reaction solution as shown in the table 2 of embodiment 3 to composition
A part (0.5 μ l) of object, reacts 4 hours at 30 DEG C.For reaction product, carry out agarose gel electrophoresis (0.5%1 ×
TBE, 60V, 55 minutes), it is dyed with SybrGreen I (Takara Shuzo Co., Ltd.), detects DNA.Show the result in Figure 11.With reality
It applies example 4 similarly, is used for the duplication of cyclic DNA in a part of the reaction mixture for the oriC transfer reaction that Tnp will be present
When amplified reaction, the generation as duplication product/amplified production supercoil product is confirmed.On the other hand, oriC transfer is anti-
It answers there is no in the case where Tnp, even if carrying out the duplication amplified reaction of cyclic DNA, does not also confirm duplication product/amplification
Product.
In addition, the additive amount of target DNA is changed to 1pM (50pg (3 × 10 in oriC transfer reaction6Molecule)/5 μ l),
0.1pM(5pg(3×105Molecule)/5 μ l), 10fM (500fg (3 × 104Molecule)/5 μ l) and 1fM (50fg (3 × 103Molecule)/
5 μ l), carry out reaction similar to the above.Show the result in Figure 12.Should the result shows that: even for ((3000 points of 50fg of 1fM
Son)/5 μ l) this very low concentration of target DNA, oriC can also be efficiently imported, and the ring-type of the application can be passed through
The duplication amplification method of DNA expands.
Embodiment 6: the amplification of the thermophilic bacteria plasmid of oriC transposons transfer is utilized
In oriC transfer reaction, 50fg is used to extract from as HB8 plants of thermus thermophilus of height Thermophilic Bacteria
The plasmid (pTT8 plasmid) of 9.3kb carries out oriC transfer reaction and ring as target DNA similarly to Example 5 in addition to this
The duplication amplified reaction of shape DNA.Show the result in Figure 13.
When pTT8 plasmid is digested with Kpn I and Nhe I, generation 5.3kb, 1.7kb as shown in the plasmid map of Figure 14,
The segment of 1.3kb and 1.0kb.Duplication product caused by above-mentioned reaction/amplified production restriction enzyme Kpn I and Nhe I is disappeared
Change.Show the result in Figure 14.Kpn I and the Nhe I of duplication product/amplified production caused by above-mentioned reaction are digested, with
PTT8 plasmid similarly confirms the segment of 5.3kb, 1.7kb, 1.3kb and 1.0kb.This shows: multiple caused by above-mentioned reaction
Product/amplified production processed is reproducible to amplify the cyclic DNA for having oriC transposons relative to the transfer of pTT8 plasmid.
These the result shows that: in the 9.3kb matter using GC containing ratio high (GC containing ratio about 70%) and heterogenous cell source
When grain, also similarly to Example 5, oriC can also efficiently be imported for very low concentration of target DNA, and can pass through
The duplication amplification method of the cyclic DNA of the application expands.
Embodiment 7: the amplification of the λ DNA of oriC transposons transfer is utilized
λ DNA is the straight-chain DNA in bacteriophage source.It is cyclized, preparation is shifted by oriC transposons and imports oriC's
Cyclic DNA carries out the duplication amplification method of the cyclic DNA of the application.
(1)Annealing and notch reparation reaction
It is following to carry out annealing reaction.λ DNA (spinning of 48kb/ Japan) 160ng/ μ l is added to buffer (10mM Tris-
HCL (pH 7.5), 50mM NaCl, 1mM EDTA) in, obtain the solution of 5 μ l.The solution is kept the temperature after five minutes at 65 DEG C,
4 DEG C are cooled to -0.5 DEG C/30 seconds cooling rates, the position COS of two ends of λ DNA is connected and is cyclized.
It is following to carry out notch reparation reaction.0.5 μ l of solution after annealing reaction is added to comprising 50nM ligase, 50nM
Pol I, 20mU/ μ l Exo III, 5nM gyrase, 0.1mg/ml BSA reaction solution (as reaction buffer, use 2 institute of table
The reaction buffer (that is, reaction buffer of the enzyme group without table 2) of the composition shown), it is reacted 16 hours at 30 DEG C.
For the reaction product of notch reparation reaction, agarose gel electrophoresis (0.5%1 × TBE, 60V, 55 points are carried out
Clock), it is dyed with SybrGreen I (Takara Shuzo Co., Ltd.), detects DNA.Show the result in Figure 15.Carrying out notch reparation
In the reaction product of reaction, observe that the band of supercoil product, supercoil product show that there are the DNA of unnotched cyclisation.
(2)The amplification of oriC transposons transfer and λ DNA
The 1 μ l of reaction product for using notch reparation to react is carried out similarly to Example 5 as the solution comprising target DNA
The duplication amplified reaction of oriC transfer reaction and cyclic DNA.Here, in the duplication amplified reaction of cyclic DNA, using to
The RecJf (NEB company) of 60nM RecG and 0.5U/ μ l is further added in the reaction solution of composition shown in the table 2 of embodiment 3
Solution.RecG be from the Bacillus coli expression strain of RecG by the inclusion of ammonium sulfate precipitation, affinity column chromatography process and give birth to
At, preparation.Show the result in Figure 16.
When λ DNA is digested with restriction enzyme HindIII, the segment of 27kb, 9.4kb, 6.6kb, 2.3kb and 2.0kb are generated.
The restriction enzyme HindIII of duplication product/amplified production caused by above-mentioned reaction is digested into (37 DEG C, 3 hours).It shows the result in
Figure 17.When digesting duplication product/amplified production caused by above-mentioned reaction with HindIII, confirmed in the same manner as λ DNA
The segment of 27kb, 9.4kb, 6.6kb, 2.3kb and 2.0kb.This shows: product/amplified production is replicated caused by above-mentioned reaction
Duplication amplifies the cyclic DNA that the DNA transfer being cyclized into relative to λ DNA has oriC transposons.
These the result shows that: for straight-chain DNA, also can use the application by carrying out oriC transfer reaction after cyclisation
Cyclic DNA duplication amplified reaction.
The removing (1) of embodiment 8:oriC transposons
Studying the oriC importeding into cyclic DNA by oriC transfer reaction could remove.
(1)Cyclic DNA
The oriC transposons of embodiment 5 includes kanamycins (Km) resistant gene and oriC.On the other hand, the large intestine of 15kb
Bacillus gene expression plasmid includes ampicillin (Amp) resistant gene.It screens and recycles anti-by the oriC transfer of embodiment 5
It is in the plasmid that should be obtained, in the region of the coding ampicillin resistance gene of the bacillus coli gene expression plasmid of 15kb
Transfer has the cyclic DNA (being denoted as p15k::Km-oriC) of oriC transposons.Specifically, making to shift by the oriC of embodiment 5
Obtained plasmid conversion Escherichia coli are reacted, Amp sensitivity, the transformant of Km tolerance are screened, to be cloned.
(2)OriC transposons falls off
By transposase, make to fall off with the comparable region of oriC transposons shifted by oriC transfer reaction.In addition,
When shifting oriC transposons by oriC transfer reaction, the region of 9bp is repeatedly formed at the both ends of oriC transposons, therefore
It is handled when removing oriC transposons, so that the region of the 9bp does not repeat to exist after connection.For extracting oriC swivel base
Sub and generation the end DNA comprising the region 9bp, uses straight-chain double-stranded DNA dependence single stranded DNA exonuclease Exo
III and the single stranded for carrying out end section.Then, single-stranded mutual annealing is carried out using the repeating part in the region 9bp, realizes ring
Change.Schematic diagram is shown in Figure 18.
Specifically, carrying out reaction below.
OriC transposons, which falls off, reacts following progress: by 0~30nM (0nM, 3nM, 10nM and 30nM) transposase and 2ng/ μ
L p15k::Km-oriC is in buffer (5 μ l;10mM Tris-HCl [pH 7.5], 150mM potassium glutamate, 10mM Mg
(oAc)2) in keep the temperature 16 hours at 37 DEG C, to carry out.Then the heat inactivation processing of 70 DEG C, 5 minutes is carried out.
It falls off to oriC transposons and Takara ExoIII buffer (50mM Tris-HCl (pH is added in 1 μ l of reaction product
8.0),5mM MgCl2, 1mM DTT), ExoIII (Takara) 20mU/ μ l, make 5 μ l of final volume.Make the mixture 30
DEG C reaction 10 minutes, carry out ExoIII processing.
Will with ExoIII, treated that reaction product is kept the temperature after five minutes at 65 DEG C, with -0.5 DEG C/30 seconds cooling rates
It is cooled to 4 DEG C and anneals.
(3)It is fallen off by conversion confirmation oriC transposons
Large intestine bar is converted using 2 μ l of sample obtained in above-mentioned (2) and Competent cell (bacillus coli DH 5 alpha) 50
Bacterium.By transformed cells be seeded into comprising 25 μ l ampicillin, 100 μ g/ml, 25 μ l kanamycins, 25 μ g/ml plate on, 37
An evening is incubated at DEG C.
The bacterium colony formation of (0nM) when being not added with transposase in above-mentioned (2) is set as 100, when calculating change swivel base enzyme concentration
Opposite Colony Forming Unit (%).
(4)As a result
Show the result in Figure 19 and Figure 20.
According to the result of Figure 19 it is found that the transformed cells of kanamycins tolerance with the concentration for the transposase being added and
It reduces.When adding transposase 30nM, the transformed cells of kanamycins tolerance are no longer present.This shows to pass through addition
Transposase can make oriC transposons fall off.
In addition, according to fig. 20 result it is found that handled dependent on ExoIII, due to oriC transposons insertion and temporary quilt
The ampicillin gene of destruction can restore.
The removing (2) of embodiment 9:oriC transposons
In parallel with ExoIII processing, to the limit using restriction enzyme position contained in the sequence for corresponding to oriC transposons
The case where enzyme processed is handled in parallel is studied.Signal is illustrated in Figure 21.
(1)Cyclic DNA
Use cyclic DNA same as Example 8.
(2)OriC transposons falls off
OriC transposons falls off to react to carry out similarly to Example 8 other than using 10nM transposase.
It falls off to oriC transposons and Takara ExoIII buffer (50mM Tris-HCl is only added in 1 μ l of reaction product
(pH 8.0),5mM MgCl2, 1mM DTT) and ExoIII (Takara) 20mU/ μ l or be added ExoIII (Takara)
20mU/ μ l and NheI (NEB) 0.6U/ μ l, makes 5 μ l of final volume.The mixture is reacted 10 minutes at 30 DEG C, is carried out
ExoIII processing.
Will with ExoIII and NheI, treated that reaction product is kept the temperature after five minutes at 65 DEG C, with -0.5 DEG C/30 seconds drops
Warm speed is cooled to 4 DEG C and anneals.
(3)It is fallen off by conversion confirmation oriC transposons
It is converted similarly to Example 8.Calculate Colony Forming Unit.
(4)As a result
Show the result in table 3
[table 3]
Should the result shows that: by by the position transposons DNA with restriction enzyme (NheI) cut off, can reduce and fail due to swivel base
The problem of enzyme and the plasmid containing transposons to fall off from cyclic DNA are remained as noise.
DNA polymer brought by embodiment 10:Cre, which generates, to be inhibited
< material and method >
By being template with pUC19 (precious biotech firm) and using primer SUE1156:5 '-
CTATGCGGCATCAGAGCAG-3 ' (sequence number 38) and SUE1361:5 '-GTTAAGCCAGCCCCGACAC-3 ' (sequence number 39)
PCR, to prepare the pUC DNA fragmentation of 2.6kb.
As cyclic DNA of the position configured with loxP sequence near oriC, it is prepared for pUC19-OLDT ring-type as follows
DNA.PUC DNA fragmentation is connected with OLDT box, is cyclized and makes.The sequence of OLDT box (0.41kb) is as follows, (small in oriC box
Write letter part) upstream side be adjacent to loxP sequence (underscore part).
OLDT box: 5 '-CGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACAGTATGTTGTAACTAA AGATAACTTCGTATAATGTATGCTATACGAAGTTATACAGATCGTGCgatctactgtggataactctgtcaggaagct
tggatcaaccggtagttatccaaagaacaactgttgttcagtttttgagttgtgtataacccctcattctgatccc
agcttatacggtccaggatcaccgatcattcacagttaatgatcctttccaggttgttgatcttaaaagccggatc
cttgttatccacagggcagtgcgatcctaataagagatcacaatagaacagatctctaaataaatagatcttcttt
ttaatacCCAGGATCCATTTAACATAATATACATTATGCGCACCTTTAGTTACAACATACTATGCGGCATCAGAGC
AGATTGTACTGAGAGTGCACCAT-3 ' (sequence number 40)
As the control cyclic DNA for not having loxP sequence, it is prepared for pUC-OriC300 cyclic DNA as follows.By pUC
DNA fragmentation is connected with OriC300 box, is cyclized and makes.The sequence of oriC300 box (0.41kb) is as follows, has oriC box (small letter
Letter part).
OriC300 box: 5 '-CGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACAGTATGTTGTAACTA
AAgatctactgtggataactctgtcaggaagcttggatcaaccggtagttatccaaagaacaactgttgttcagtt
tttgagttgtgtataacccctcattctgatcccagcttatacggtccaggatcaccgatcattcacagttaatgat
cctttccaggttgttgatcttaaaagccggatccttgttatccacagggcagtgcgatcctaataagagatcacaa
tagaacagatctctaaataaatagatcttctttttaatacTTTAGTTACAACATACTATGCGGCATCAGAGCAGAT
TGTACTGAGAGTGCACCAT-3 ' (sequence number 41)
Cre uses the product bought from NEB company.
Prepare the reaction solution of composition shown in the table 2 of embodiment 3 and other than forming shown in table 2 also with final concentration
1mU/ μ l, 3mU/ μ l, 10mU/ μ l or 30mU/ μ l are added with the reaction solution of Cre.Into these reaction solutions respectively with final concentration
The mode of 0.01ng/ μ l adds pUC19-OLDT cyclic DNA or pUC-OriC300 cyclic DNA, after mixing on ice, at 33 DEG C
Incubator in keep the temperature 3 hours and make its reaction.
For reaction product, carry out agarose gel electrophoresis (0.5%1 × TBE, 60V, 60 minutes), with SybrGreen I
(Takara Shuzo Co., Ltd.) dyes and detects DNA.
< result >
The testing result for replicating amplified production is shown in Figure 22.
May validate that use pUC-OLDT cyclic DNA that loxP sequence is configured near oriC as template and anti-
It answers in liquid and is produced comprising in the case where Cre, inhibiting the generation of the polymer as by-product and replicating or amplify target supercoil
The cyclic DNA of object structure.At this point, the appearance of the intermediate product from polymer to monomer separation also can be observed.In addition, by by
The Cre concentration in reaction solution is gradually improved, the effect of the generation of polymer is inhibited also to improve.
When using the pUC19-OriC300 cyclic DNA without loxP sequence as template, the effect of Cre is not observed
Fruit.
Industrial availability
By the invention it is possible to which providing conveniently and efficiently can replicate or expand cyclic DNA, particularly long-chain cyclic DNA
Method.
Sequence number 1:ter sequence (consensus sequence)
Sequence number 2:ter sequence (consensus sequence)
Sequence number 3:ter sequence (terA, B, D, E, or H)
Sequence number 4:ter sequence (terA, B, D, E, or H)
Sequence number 5:ter sequence (terC)
Sequence number 6:ter sequence (terF)
Sequence number 7:ter sequence (terG)
Sequence number 8:ter sequence (terI)
Sequence number 9:ter sequence (tarJ)
Sequence number 10:ter sequence (bacillus, consensus sequence)
Sequence number 11:ter sequence (bacillus subtilis, consensus sequence)
Sequence number 12:ter sequence (bacillus subtilis, consensus sequence)
Sequence number 13:ter sequence (terVII)
Sequence number 14:ter sequence (terIX)
Sequence number 15: the sequence (consensus sequence) identified by XerCD
Sequence number 16: the sequence (consensus sequence, dif and cer) identified by XerCD
Sequence number 17: the sequence (consensus sequence, dif and psi) identified by XerCD
Sequence number 18: the sequence (consensus sequence, cer and psi) identified by XerCD
Sequence number 19:dif sequence
Sequence number 20:cer sequence
Sequence number 21:psi sequence
Sequence number 22:dif sequence
Sequence number 23:cer sequence
Sequence number 24:psi sequence
Sequence number 25: outer end (OE) sequence
Sequence number 26: the DNA fragmentation comprising 1 pair of ter sequence
Sequence number 27:ori-ter box
Sequence number 28:ori-dif box
Sequence number 29:oriC transposons
Sequence number 30:loxP consensus sequence
Sequence number 31:lox511 sequence
Sequence number 32:lox2272 sequence
Sequence number 33:loxFAS sequence
Sequence number 34:lox RE sequence
Sequence number 35:lox LE sequence
Sequence number 36:FRT sequence
Sequence number 37:rox sequence
Sequence number 38: primer SUE1156
Sequence number 39: primer SUE1361
Sequence number 40:OLDT box
Sequence number 41:OriC300 box
Sequence table
<110>state-run research and development legal person Science and Technology Agency (Japan Science and Technology
Agency)
<120>duplication of cyclic DNA or amplification method
<130> FA4002-17267
<150> JP 2017-037489
<151> 2017-02-28
<160> 41
<170> PatentIn version 3.5
<210> 1
<211> 14
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (consensus sequence)
<220>
<221> misc_feature
<222> (2)..(2)
<223>n is a, c, g, or t
<220>
<221> misc_feature
<222> (3)..(3)
<223>r is a or g
<220>
<221> misc_feature
<222> (4)..(4)
<223>w is a or t
<220>
<221> misc_feature
<222> (13)..(13)
<223>k is g or t
<400> 1
gnrwgttgta acka 14
<210> 2
<211> 14
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (consensus sequence)
<220>
<221> misc_feature
<222> (2)..(2)
<223>k is g or t
<220>
<221> misc_feature
<222> (4)..(4)
<223>w is a or t
<220>
<221> misc_feature
<222> (13)..(13)
<223>k is g or t
<400> 2
gkawgttgta acka 14
<210> 3
<211> 14
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (terA, B, D, E, or H)
<400> 3
gtatgttgta acta 14
<210> 4
<211> 18
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (terA, B, D, E, or H)
<400> 4
agtatgttgt aactaaag 18
<210> 5
<211> 14
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (terC)
<400> 5
ggatgttgta acta 14
<210> 6
<211> 14
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (terF)
<400> 6
gtatgttgta acga 14
<210> 7
<211> 14
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (terG)
<400> 7
ggatgttgta acta 14
<210> 8
<211> 14
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (terI)
<400> 8
ggaagttgta acga 14
<210> 9
<211> 14
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (terJ)
<400> 9
gtaagttgta acga 14
<210> 10
<211> 23
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (bacillus (Bacillus), consensus sequence)
<220>
<221> misc_feature
<222> (3)..(3)
<223>w is a or t
<220>
<221> misc_feature
<222> (4)..(4)
<223>r is a or g
<220>
<221> misc_feature
<222> (6)..(10)
<223>n is a, c, g or t
<220>
<221> misc_feature
<222> (11)..(11)
<223>y is t or c
<220>
<221> misc_feature
<222> (12)..(12)
<223>n is a, c, g or t
<220>
<221> misc_feature
<222> (19)..(19)
<223>n is a, c, g or t
<400> 10
acwrannnnn ynatgtacna aat 23
<210> 11
<211> 23
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (bacillus subtilis (Bacillus subtilis), consensus sequence)
<220>
<221> misc_feature
<222> (8)..(8)
<223>r is a or g
<220>
<221> misc_feature
<222> (10)..(10)
<223>w is a or t
<220>
<221> misc_feature
<222> (12)..(12)
<223>y is c or t
<400> 11
actaattraw cyatgtacta aat 23
<210> 12
<211> 28
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (bacillus subtilis (Bacillus subtilis), consensus sequence)
<220>
<221> misc_feature
<222> (8)..(8)
<223>r is a or g
<220>
<221> misc_feature
<222> (10)..(10)
<223>w is a or t
<220>
<221> misc_feature
<222> (12)..(12)
<223>y is c or t
<400> 12
actaattraw cyatgtacta aattttca 28
<210> 13
<211> 30
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (terVII)
<400> 13
gaactaatta aactatgtac taaattttca 30
<210> 14
<211> 30
<212> DNA
<213>artificial sequence
<220>
<223>ter sequence (terIX)
<400> 14
atactaattg atccatgtac taaattttca 30
<210> 15
<211> 28
<212> DNA
<213>artificial sequence
<220>
<223>sequence (consensus sequence) identified by XerCD
<220>
<221> misc_feature
<222> (7)..(7)
<223>y is c or t
<220>
<221> misc_feature
<222> (8)..(8)
<223>r is a or g
<220>
<221> misc_feature
<222> (9)..(9)
<223>y is c or t
<220>
<221> misc_feature
<222> (12)..(17)
<223>n is a, c, g or t
<220>
<221> misc_feature
<222> (23)..(23)
<223>k is g or t
<220>
<221> misc_feature
<222> (28)..(28)
<223>y is c or t
<400> 15
ggtgcgyrya annnnnntta tgktaaay 28
<210> 16
<211> 28
<212> DNA
<213>artificial sequence
<220>
<223>sequence (consensus sequence, dif and cer) identified by XerCD
<220>
<221> misc_feature
<222> (7)..(7)
<223>y is c or t
<220>
<221> misc_feature
<222> (9)..(9)
<223>y is c or t
<220>
<221> misc_feature
<222> (12)..(17)
<223>n is a, c, g or t
<220>
<221> misc_feature
<222> (23)..(23)
<223>k is g or t
<400> 16
ggtgcgyaya annnnnntta tgktaaat 28
<210> 17
<211> 28
<212> DNA
<213>artificial sequence
<220>
<223>sequence (consensus sequence, dif and psi) identified by XerCD
<220>
<221> misc_feature
<222> (9)..(9)
<223>y is c or t
<220>
<221> misc_feature
<222> (12)..(17)
<223>n is a, c, g, or t
<220>
<221> misc_feature
<222> (28)..(28)
<223>y is c or t
<400> 17
ggtgcgcrya annnnnntta tgttaaay 28
<210> 18
<211> 28
<212> DNA
<213>artificial sequence
<220>
<223>sequence (consensus sequence, cer and psi) identified by XerCD
<220>
<221> misc_feature
<222> (7)..(7)
<223>y is c or t
<220>
<221> misc_feature
<222> (8)..(8)
<223>r is a or g
<220>
<221> misc_feature
<222> (12)..(17)
<223>n is a, c, g, or t
<220>
<221> misc_feature
<222> (23)..(23)
<223>k is g or t
<220>
<221> misc_feature
<222> (28)..(28)
<223>y is c or t
<400> 18
ggtgcgyrca annnnnntta tgktaaay 28
<210> 19
<211> 28
<212> DNA
<213>artificial sequence
<220>
<223>dif sequence
<220>
<221> misc_feature
<222> (12)..(17)
<223>n is a, c, g, or t
<400> 19
ggtgcgcata annnnnntta tgttaaat 28
<210> 20
<211> 28
<212> DNA
<213>artificial sequence
<220>
<223>cer sequence
<220>
<221> misc_feature
<222> (12)..(17)
<223>n is a, c, g, or t
<400> 20
ggtgcgtaca annnnnntta tggtaaat 28
<210> 21
<211> 28
<212> DNA
<213>artificial sequence
<220>
<223>psi sequence
<220>
<221> misc_feature
<222> (12)..(17)
<223>n is a, c, g, or t
<400> 21
ggtgcgcgca annnnnntta tgttaaac 28
<210> 22
<211> 28
<212> DNA
<213>artificial sequence
<220>
<223>dif sequence
<400> 22
ggtgcgcata atgtatatta tgttaaat 28
<210> 23
<211> 28
<212> DNA
<213>artificial sequence
<220>
<223>cer sequence
<400> 23
ggtgcgtaca agggatgtta tggtaaat 28
<210> 24
<211> 28
<212> DNA
<213>artificial sequence
<220>
<223>psi sequence
<400> 24
ggtgcgcgca agatccatta tgttaaac 28
<210> 25
<211> 19
<212> DNA
<213>artificial sequence
<220>
<223>outer end (OE) sequence
<400> 25
ctgtctctta tacacatct 19
<210> 26
<211> 222
<212> DNA
<213>artificial sequence
<220>
<223>comprising the DNA fragmentation of 1 pair of ter sequence
<220>
<221> misc_feature
<222> (24)..(199)
<220>
<221> misc_feature
<222> (24)..(199)
<223>n is a, c, g, or t
<400> 26
actttagtta caacatactt attnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 120
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180
nnnnnnnnnn nnnnnnnnna ataagtatgt tgtaactaaa gt 222
<210> 27
<211> 383
<212> DNA
<213>artificial sequence
<220>
<223>ori-ter box
<400> 27
agtatgttgt aactaaagat aacttcgtat aatgtatgct atacgaagtt atacagatcg 60
tgcgatctac tgtggataac tctgtcagga agcttggatc aaccggtagt tatccaaaga 120
acaactgttg ttcagttttt gagttgtgta taacccctca ttctgatccc agcttatacg 180
gtccaggatc accgatcatt cacagttaat gatcctttcc aggttgttga tcttaaaagc 240
cggatccttg ttatccacag ggcagtgcga tcctaataag agatcacaat agaacagatc 300
tctaaataaa tagatcttct ttttaatacc caggatccat ttaacataat atacattatg 360
cgcaccttta gttacaacat act 383
<210> 28
<211> 320
<212> DNA
<213>artificial sequence
<220>
<223>ori-dif box
<400> 28
atttaacata atatacatta tgcgcaccaa gtatacagat cgtgcgatct actgtggata 60
actctgtcag gaagcttgga tcaaccggta gttatccaaa gaacaactgt tgttcagttt 120
ttgagttgtg tataacccct cattctgatc ccagcttata cggtccagga tcaccgatca 180
ttcacagtta atgatccttt ccaggttgtt gatcttaaaa gccggatcct tgttatccac 240
agggcagtgc gatcctaata agagatcaca atagaacaga tctctaaata aatagatctt 300
ctttttaata cccaggatcc 320
<210> 29
<211> 399
<212> DNA
<213>artificial sequence
<220>
<223>oriC transposons DNA
<400> 29
ctgtctctta tacacatctg aagatccggc agaagaatgg ctgggatcgt gggttaattt 60
actcaaataa gtatacagat cgtgcgatct actgtggata actctgtcag gaagcttgga 120
tcaaccggta gttatccaaa gaacaactgt tgttcagttt ttgagttgtg tataacccct 180
cattctgatc ccagcttata cggtccagga tcaccgatca ttcacagtta atgatccttt 240
ccaggttgtt gatcttaaaa gccggatcct tgttatccac agggcagtgc gatcctaata 300
agagatcaca atagaacaga tctctaaata aatagatctt ctttttaata cccaggatcc 360
caggtctttc tcaagccgac agatgtgtat aagagacag 399
<210> 30
<211> 34
<212> DNA
<213>artificial sequence
<220>
<223>loxP consensus sequence
<400> 30
ataacttcgt atagcataca ttatacgaag ttat 34
<210> 31
<211> 34
<212> DNA
<213>artificial sequence
<220>
<223>511 sequence of lox
<400> 31
ataacttcgt atagtataca ttatacgaag ttat 34
<210> 32
<211> 34
<212> DNA
<213>artificial sequence
<220>
<223>lox2272 sequence
<400> 32
ataacttcgt ataggatact ttatacgaag ttat 34
<210> 33
<211> 34
<212> DNA
<213>artificial sequence
<220>
<223>loxFAS sequence
<400> 33
ataacttcgt atataccttt ctatacgaag ttat 34
<210> 34
<211> 34
<212> DNA
<213>artificial sequence
<220>
<223>lox RE sequence
<400> 34
ataacttcgt atagcataca ttatacgaac ggta 34
<210> 35
<211> 34
<212> DNA
<213>artificial sequence
<220>
<223>lox LE sequence
<400> 35
taccgttcgt atagcataca ttatacgaag ttat 34
<210> 36
<211> 34
<212> DNA
<213>artificial sequence
<220>
<223>FRT sequence
<400> 36
gaagttccta ttctctagaa agtataggaa cttc 34
<210> 37
<211> 32
<212> DNA
<213>artificial sequence
<220>
<223>rox sequence
<400> 37
taactttaaa taatgccaat tatttaaagt ta 32
<210> 38
<211> 19
<212> DNA
<213>artificial sequence
<220>
<223>SUE1156 primer
<400> 38
ctatgcggca tcagagcag 19
<210> 39
<211> 19
<212> DNA
<213>artificial sequence
<220>
<223>SUE1361 primer
<400> 39
gttaagccag ccccgacac 19
<210> 40
<211> 461
<212> DNA
<213>artificial sequence
<220>
<223>OLDT box
<400> 40
cgcgtcagcg ggtgttggcg ggtgtcgggg ctggcttaac agtatgttgt aactaaagat 60
aacttcgtat aatgtatgct atacgaagtt atacagatcg tgcgatctac tgtggataac 120
tctgtcagga agcttggatc aaccggtagt tatccaaaga acaactgttg ttcagttttt 180
gagttgtgta taacccctca ttctgatccc agcttatacg gtccaggatc accgatcatt 240
cacagttaat gatcctttcc aggttgttga tcttaaaagc cggatccttg ttatccacag 300
ggcagtgcga tcctaataag agatcacaat agaacagatc tctaaataaa tagatcttct 360
ttttaatacc caggatccat ttaacataat atacattatg cgcaccttta gttacaacat 420
actatgcggc atcagagcag attgtactga gagtgcacca t 461
<210> 41
<211> 378
<212> DNA
<213>artificial sequence
<220>
<223>oriC300 box
<400> 41
cgcgtcagcg ggtgttggcg ggtgtcgggg ctggcttaac agtatgttgt aactaaagat 60
ctactgtgga taactctgtc aggaagcttg gatcaaccgg tagttatcca aagaacaact 120
gttgttcagt ttttgagttg tgtataaccc ctcattctga tcccagctta tacggtccag 180
gatcaccgat cattcacagt taatgatcct ttccaggttg ttgatcttaa aagccggatc 240
cttgttatcc acagggcagt gcgatcctaa taagagatca caatagaaca gatctctaaa 300
taaatagatc ttctttttaa tactttagtt acaacatact atgcggcatc agagcagatt 360
gtactgagag tgcaccat 378
Claims (16)
1. a kind of clone method of the cyclic DNA in cell free system, it includes processes below:
Process (1): being formed into the cyclic DNA of template and the reaction mixture of reaction solution, and the reaction solution includes following components:
First enzyme group of the duplication of catalysis cyclic DNA,
Catalysis Okazaki fragments connection reaction and be synthetically formed 2 sisters' cyclic DNAs of catenane second enzyme group and
It is catalyzed the third enzyme group of the separation reaction of 2 sisters' cyclic DNAs;With
Process (2): react the reaction mixture formed in process (1);
Wherein, the cyclic DNA include can with replication initiation sequence (the origin of in conjunction with the active enzyme of DnaA
Chromosome (oriC)) and also comprising being respectively relative to 1 pair of ter sequence that oriC is inserted into outward and/or by DNA poly
Body separates the base sequence of enzyme identification,
Wherein, in the case where the cyclic DNA has ter sequence, the reaction solution of the process (1) also includes to have to be incorporated into
Ter sequence and inhibit duplication active protein, also, the cyclic DNA have DNA polymer separation enzyme identification base
In the case where sequence, the reaction solution of the process (1) also includes DNA polymer separation enzyme.
2. according to the method described in claim 1, wherein, it is Cre or XerCD that DNA polymer, which separates enzyme,.
3. method according to claim 1 or 2, wherein be just respectively relative to 1 pair of ter sequence that oriC is inserted into outward and
Speech, the ter sequence as a side is in the 5 ' sides of oriC inserted with including any sequence in sequence shown in sequence number 1~14
Sequence, as another party ter sequence in the 3 ' sides of oriC inserted with the complementary series comprising sequence shown in sequence number 1~14
Sequence.
4. according to the method in any one of claims 1 to 3, wherein have the work for being incorporated into ter sequence and inhibiting duplication
Property protein be Tus albumen or RTP albumen.
5. according to the method described in claim 2, wherein, the base sequence of XerCD identification is comprising shown in sequence number 15~24
Sequence in any sequence sequence or its complementary series.
6. according to the method described in claim 2, wherein, the base sequence of Cre identification is comprising shown in sequence number 30~35
The sequence of any sequence in sequence or its complementary series.
7. a kind of nucleic acid comprising oriC and is respectively relative to oriC for the linear DNA of the length with 273bp~2.0kb
The base sequence for 1 pair of ter sequence and/or DNA polymer the separation enzyme identification being inserted into outward.
8. a kind of clone method of the cyclic DNA in cell free system, it includes processes below:
Process (1): oriC transposons and transposase are added in buffer and form oriC swivel base body, wherein oriC swivel base
Son for comprising can with the replication initiation sequence (origin of chromosome (oriC)) in conjunction with the active enzyme of DnaA
Linear DNA and its two end include outer end (OE) sequence;With
It reacts oriC swivel base body and the cyclic DNA without oriC in buffer, carries out transfer reaction;
Thus the cyclic DNA comprising oriC is prepared;
Process (2): the reaction mixture of the cyclic DNA and reaction solution obtained in (1) comprising oriC, the reaction solution packet are formed
Containing following components:
First enzyme group of the duplication of catalysis cyclic DNA,
Catalysis Okazaki fragments connection reaction and be synthetically formed 2 sisters' cyclic DNAs of catenane second enzyme group and
It is catalyzed the third enzyme group of the separation reaction of 2 sisters' cyclic DNAs;With
Process (3): react the reaction mixture formed in process (2).
9. according to the method described in claim 8, wherein, OE sequence includes 25 (5 '-CTGTCTCTTATACACATCT- of sequence number
3 ') sequence and its complementary series shown in, process (1) linear DNA 5 ' ends inserted with comprising shown in sequence number 25
The OE sequence of sequence, in OE sequence of the 3 ' ends of the linear DNA inserted with the complementary series comprising sequence shown in sequence number 25
Column.
10. method according to claim 8 or claim 9 is comprising the cyclic DNA of oriC also includes to be respectively relative to oriC
The base sequence for 1 pair of ter sequence and/or DNA polymer the separation enzyme identification being inserted into outward,
Wherein, in the case where the cyclic DNA has ter sequence, the reaction solution of the process (2) also includes to have to be incorporated into
Ter sequence and inhibit duplication active protein, also, the cyclic DNA have DNA polymer separation enzyme identification base
In the case where sequence, the reaction solution of the process (2) also includes DNA polymer separation enzyme.
11. the method according to any one of claim 8 to 10, wherein the oriC transposons of process (1) also includes difference
The base sequence of enzyme identification is separated relative to oriC 1 pair of ter sequence being inserted into outward and/or DNA polymer,
Wherein, in the case where the linear DNA has ter sequence, the reaction solution of the process (2) also includes to have to be incorporated into
Ter sequence and inhibit duplication active protein, also, the cyclic DNA have DNA polymer separation enzyme identification base
In the case where sequence, the reaction solution of the process (2) also includes DNA polymer separation enzyme.
12. the method according to any one of claim 8 to 11, wherein also include process (4): from the anti-of process (3)
The cyclic DNA for replicating or expanding in product is answered to remove oriC transposons.
13. a kind of nucleic acid comprising oriC and is respectively relative to oriC for the linear DNA of the length with 311bp~2.0kb
The base sequence for 1 pair of ter sequence and/or DNA polymer the separation enzyme identification being inserted into outward, and include outer end in two ends
(OE) sequence.
14. a kind of duplication kit of cyclic DNA, it includes the combinations of following components:
It is catalyzed the first enzyme group of the duplication of cyclic DNA;
The second enzyme group of 2 sisters' cyclic DNAs of catenane is reacted and is synthetically formed in catalysis Okazaki fragments connection;
It is catalyzed the third enzyme group of the separation reaction of 2 sisters' cyclic DNAs;
OriC transposons, wherein oriC transposons be comprising can with the replication initiation sequence in conjunction with the active enzyme of DnaA
The linear DNA of (origin of chromosome (oriC)) and be its two end include outer end (OE) sequence traditional thread binding DNA;With
Transposase.
15. kit according to claim 14, wherein oriC transposons also includes to be respectively relative to oriC to be inserted into outward
1 pair of ter sequence and/or DNA polymer separation enzyme identification base sequence.
16. kit according to claim 15, wherein also comprising inhibiting the work replicated with ter sequence is incorporated into
The protein of property;And/or DNA polymer separates enzyme.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017037489 | 2017-02-28 | ||
JP2017-037489 | 2017-02-28 | ||
PCT/JP2018/007485 WO2018159669A1 (en) | 2017-02-28 | 2018-02-28 | Method for replicating or amplifying circular dna |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110446783A true CN110446783A (en) | 2019-11-12 |
Family
ID=63371371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880018564.4A Pending CN110446783A (en) | 2017-02-28 | 2018-02-28 | The duplication of cyclic DNA or amplification method |
Country Status (12)
Country | Link |
---|---|
US (2) | US11685940B2 (en) |
EP (1) | EP3591051A4 (en) |
JP (1) | JP6960684B2 (en) |
KR (1) | KR102491725B1 (en) |
CN (1) | CN110446783A (en) |
AU (1) | AU2018228154A1 (en) |
BR (1) | BR112019017657A2 (en) |
CA (1) | CA3054881A1 (en) |
IL (1) | IL268944A (en) |
RU (1) | RU2752611C2 (en) |
SG (1) | SG11201907899TA (en) |
WO (1) | WO2018159669A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112424351A (en) * | 2018-07-30 | 2021-02-26 | 奥利希罗基因组学有限公司 | Method for editing DNA in cell-free system |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3222717T3 (en) | 2014-11-18 | 2020-06-29 | Oriciro Genomics Inc | PROCEDURE FOR AMPLIFYING CIRCULAR DNA |
US10174295B1 (en) * | 2017-08-01 | 2019-01-08 | The Charles Stark Draper Laboratory, Inc. | Composition of matter: engineering of Escherichia coli phage K1E |
AU2020351204A1 (en) | 2019-09-18 | 2022-04-21 | Aldevron, Llc | Synthetic DNA vectors and methods of use |
US20220025460A1 (en) * | 2020-07-21 | 2022-01-27 | The University Of Tokyo | Method and kit for determining neuromuscular disease in subject |
TW202338094A (en) * | 2022-01-19 | 2023-10-01 | 日商奥利希羅基因組學有限公司 | Functional DNA cassette and plasmid |
WO2023191034A1 (en) * | 2022-03-31 | 2023-10-05 | モデルナ・エンザイマティクス株式会社 | Method for producing double-stranded dna molecules having reduced sequence errors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107002069A (en) * | 2014-11-18 | 2017-08-01 | 国立研究开发法人科学技术振兴机构 | The amplification method of cyclic DNA |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
US6355450B1 (en) * | 1995-04-21 | 2002-03-12 | Human Genome Sciences, Inc. | Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof |
BR0011765A (en) * | 1999-06-18 | 2002-03-05 | Aventis Pharma Inc | Vectors to improve cloning and expression in low copy number plasmids |
JP4214230B2 (en) | 2004-02-23 | 2009-01-28 | 独立行政法人農業・食品産業技術総合研究機構 | Method for introducing random mutation into circular DNA |
US8431376B2 (en) | 2004-04-26 | 2013-04-30 | The Regents Of The University Of Colorado | Bacterial replication systems and methods |
US20080096258A1 (en) | 2006-10-24 | 2008-04-24 | Christian Korfhage | Rolling circle amplification of circular genomes |
US8921072B2 (en) | 2008-09-02 | 2014-12-30 | General Electric Compnay | Methods to generate DNA mini-circles |
JP6764193B2 (en) | 2016-05-17 | 2020-09-30 | オリシロジェノミクス株式会社 | Circular DNA amplification method |
-
2018
- 2018-02-28 EP EP18760468.1A patent/EP3591051A4/en active Pending
- 2018-02-28 CA CA3054881A patent/CA3054881A1/en active Pending
- 2018-02-28 US US16/489,428 patent/US11685940B2/en active Active
- 2018-02-28 RU RU2019130498A patent/RU2752611C2/en active
- 2018-02-28 WO PCT/JP2018/007485 patent/WO2018159669A1/en unknown
- 2018-02-28 KR KR1020197027017A patent/KR102491725B1/en active IP Right Grant
- 2018-02-28 SG SG11201907899TA patent/SG11201907899TA/en unknown
- 2018-02-28 AU AU2018228154A patent/AU2018228154A1/en active Pending
- 2018-02-28 CN CN201880018564.4A patent/CN110446783A/en active Pending
- 2018-02-28 JP JP2019503056A patent/JP6960684B2/en active Active
- 2018-02-28 BR BR112019017657A patent/BR112019017657A2/en unknown
-
2019
- 2019-08-27 IL IL26894419A patent/IL268944A/en unknown
-
2022
- 2022-11-04 US US18/052,783 patent/US20240018561A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107002069A (en) * | 2014-11-18 | 2017-08-01 | 国立研究开发法人科学技术振兴机构 | The amplification method of cyclic DNA |
Non-Patent Citations (1)
Title |
---|
H HIASA: "Topoisomerase IV can support oriC DNA replication in vitro", 《J BIOL CHEM.》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112424351A (en) * | 2018-07-30 | 2021-02-26 | 奥利希罗基因组学有限公司 | Method for editing DNA in cell-free system |
Also Published As
Publication number | Publication date |
---|---|
IL268944A (en) | 2019-10-31 |
EP3591051A1 (en) | 2020-01-08 |
US20200115727A1 (en) | 2020-04-16 |
US11685940B2 (en) | 2023-06-27 |
WO2018159669A1 (en) | 2018-09-07 |
RU2019130498A3 (en) | 2021-03-30 |
RU2752611C2 (en) | 2021-07-29 |
KR20190123287A (en) | 2019-10-31 |
BR112019017657A2 (en) | 2020-04-07 |
CA3054881A1 (en) | 2018-09-07 |
KR102491725B1 (en) | 2023-01-27 |
RU2019130498A (en) | 2021-03-30 |
JP6960684B2 (en) | 2021-11-05 |
US20240018561A1 (en) | 2024-01-18 |
AU2018228154A1 (en) | 2019-09-26 |
SG11201907899TA (en) | 2019-09-27 |
EP3591051A4 (en) | 2021-01-06 |
JPWO2018159669A1 (en) | 2020-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110446783A (en) | The duplication of cyclic DNA or amplification method | |
CN109844134B (en) | Production of closed linear DNA | |
CN113874504B (en) | Nucleic acid construct and method for producing same | |
US8741560B2 (en) | Stable compositions for nucleic acid amplification and sequencing | |
JP4227196B2 (en) | Generation and use of averaged DNA libraries | |
JP6745599B2 (en) | Preparation of molecule | |
JP6262877B2 (en) | Method for amplifying circular DNA | |
CN104093850B (en) | For reducing method and the test kit of non-specific nucleic acid amplification | |
CN109415718B (en) | Amplification method of circular DNA | |
JP7025552B2 (en) | How to edit DNA in a cell-free system | |
KR102278495B1 (en) | DNA production method and kit for linking DNA fragments | |
JP2018506989A (en) | Nucleic acid amplification and library preparation | |
CN109706233A (en) | A kind of amplification technique of complexity long-fragment nucleic acid sequence | |
JP2023543602A (en) | Targeted sequence addition | |
TW202338094A (en) | Functional DNA cassette and plasmid | |
Siegmund | DNA and RNA Polymerases with Expanded Substrate Scope: Synthesis of Modified Nucleic Acids Using Engineered Polymerases Generated by Directed Evolution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Country or region after: Japan Address after: Tokyo Applicant after: Modena Enzyme Co.,Ltd. Address before: Tokyo Applicant before: Orihiro Genomics Co.,Ltd. Country or region before: Japan |
|
CB02 | Change of applicant information |